Comparison with Similar Reports

Clinical Trial Supplies Market by Services (Manufacturing, Packaging, Logistics, Distribution), Phases (I to IV), Type (Small molecule, Biologics, Med...

Publisher: MarketsandMarkets

# of Pages: 233

Publication Date: July, 2021

Price: $4,950 / User License

1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.2.1 INCLUSIONS & EXCLUSIONS 34
1.3 MARKET SCOPE 35
1.3.1 MARKETS COVERED 35
1.3.2 YEARS CONSIDERED FOR THE STUDY 36
1.4 CURRENCY 36
1.5 LIMITATIONS 36
1.6 STAKEHOLDERS 36
1.7 SUMMARY OF CHANGES 37
2 RESEARCH METHODOLOGY 38
2.1 RESEARCH APPROACH 38
FIGURE 1 RESEARCH DESIGN 38
2.1.1 SECONDARY DATA 38
2.1.2 PRIMARY DATA 39
FIGURE 2 BREAKDOWN OF PRIMARIES: CLINICAL TRIAL SUPPLIES MARKET 40
2.1.3 MARKET DATA ESTIMATION & TRIANGULATION 41
FIGURE 3 DATA TRIANGULATION METHODOLOGY 41
2.2 MARKET ESTIMATION METHODOLOGY 42
FIGURE 4 MARKET SIZE ESTIMATION APPROACH: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH) 42
FIGURE 5 MARKET SIZE ESTIMATION APPROACH: PARENT MARKET
(TOP-DOWN APPROACH) 42
FIGURE 6 CLINICAL TRIAL SUPPLIES MARKET: FINAL MARKET SIZE (USD BILLION) 43
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST 44
FIGURE 7 GROWTH RATE ASSUMPTION BASED ON MARKET DYNAMICS 44
FIGURE 8 FINAL CAGR PROJECTIONS (2021−2026) 44
2.4 INSIGHTS FROM PRIMARIES 45
FIGURE 9 MARKET VALIDATION FROM PRIMARY EXPERTS 45
2.5 RESEARCH ASSUMPTIONS 45
2.6 RISK ASSESSMENT 45
TABLE 1 RISK ASSESSMENT 45
3 EXECUTIVE SUMMARY 46
FIGURE 10 CLINICAL TRIAL SUPPLIES MARKET SHARE, BY TYPE, 2020 VS. 2026 46
FIGURE 11 CLINICAL TRIAL SUPPLIES MARKET SHARE, BY SERVICE, 2020 47
FIGURE 12 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021 VS. 2026 47
FIGURE 13 CLINICAL TRIAL SUPPLIES MARKET SHARE, BY THERAPEUTIC AREA, 2020 48
FIGURE 14 CLINICAL TRIAL SUPPLIES MARKET SHARE, BY END USER, 2020 48
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF THE CLINICAL TRIAL SUPPLIES MARKET 49
4 PREMIUM INSIGHTS 50
4.1 CLINICAL TRIAL SUPPLIES MARKET OVERVIEW 50
FIGURE 16 INCREASING R&D INVESTMENTS TO DRIVE MARKET GROWTH 50
4.2 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET SHARE, BY TYPE & COUNTRY (2020) 51
FIGURE 17 SMALL-MOLECULE DRUGS ACCOUNTED FOR THE LARGEST SHARE OF
THE CLINICAL TRIAL SUPPLIES MARKET IN NORTH AMERICA 51
4.3 CLINICAL TRIAL SUPPLIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 52
FIGURE 18 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH IN THE CLINICAL TRIAL SUPPLIES MARKET FROM 2021 TO 2026 52
5 MARKET OVERVIEW 53
5.1 INTRODUCTION 53
5.2 MARKET DYNAMICS 53
FIGURE 19 CLINICAL TRIAL SUPPLIES MARKET: DRIVERS,
RESTRAINTS, AND OPPORTUNITIES 53
5.3 IMPACT ANALYSIS 54
5.3.1 DRIVERS 54
5.3.1.1 Increasing R&D expenditure of pharmaceutical and biopharmaceutical companies 54
TABLE 2 R&D EXPENDITURE OF LEADING PHARMACEUTICAL COMPANIES IN 2019 54
FIGURE 20 NUMBER OF PHARMA COMPANIES WITH ACTIVE DRUG PIPELINE PROJECTS (2010–2020) 55
FIGURE 21 GLOBAL R&D SPENDING (2016–2020) 55
5.3.1.2 Increasing number of registered clinical trials 56
FIGURE 22 NUMBER OF CLINICAL TRIALS IN THE LAST 10 YEARS 56
5.3.1.3 Increasing decentralization of clinical trials 56
5.3.2 RESTRAINTS 56
5.3.2.1 High cost of drug development 56
5.3.3 OPPORTUNITIES 57
5.3.3.1 Emerging markets 57
5.4 RANGES/SCENARIOS 57
FIGURE 23 DEPENDING ON HOW UNCERTAINTIES UNFOLD, WE SEE A SPECTRUM OF SCENARIOS FOR THE CLINICAL TRIAL SUPPLIES MARKET 57
5.5 COVID-19 IMPACT ANALYSIS 58
FIGURE 24 NUMBER OF CLINICAL TRIALS, BY PHASE (2020–2021) 58
FIGURE 25 NUMBER OF CLINICAL TRIALS, BY COUNTRY 58
5.6 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 59
FIGURE 26 PRE-COVID-19 VS. POST-COVID-19 SCENARIO 59

5.7 VALUE CHAIN ANALYSIS 60
FIGURE 27 VALUE CHAIN ANALYSIS OF THE CLINICAL TRIAL SUPPLIES MARKET 60
5.8 ECOSYSTEM/MARKET MAP 60
5.9 SUPPLY CHAIN 61
5.10 PORTER’S FIVE FORCES ANALYSIS 62
5.10.1 PORTER’S 5 FORCES IMPACT ON THE CLINICAL TRIAL SUPPLIES MARKET 62
5.10.1.1 Threat from new entrants 62
5.10.1.2 Threat from substitutes 63
5.10.1.3 Bargaining power of suppliers 63
5.10.1.4 Bargaining power of buyers 63
5.10.1.5 Degree of competition 63
5.11 REGULATORY LANDSCAPE 64
5.11.1 INTRODUCTION 64
6 CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE 68
6.1 INTRODUCTION 69
TABLE 3 CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION) 69
6.2 LOGISTICS & DISTRIBUTION 69
6.2.1 INCREASING COMPLEXITY, EVOLVING TREATMENT PROTOCOLS, TECHNOLOGICAL ADVANCEMENTS, AND DATA SECURITY CHALLENGES TO DRIVE THE DEMAND FOR LOGISTICS & DISTRIBUTION SERVICES 69
TABLE 4 CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY REGION, 2019–2026 (USD MILLION) 70
TABLE 5 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2019–2026 (USD MILLION) 70
TABLE 6 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2019–2026 (USD MILLION) 70
TABLE 7 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2019–2026 (USD MILLION) 71
6.3 STORAGE & RETENTION 71
6.3.1 GROWING DEMAND FOR DIRECT-TO-PATIENT AND DIRECT-TO-SITE
SERVICES TO DRIVE GROWTH IN THE STORAGE & RETENTION SERVICES MARKET SEGMENT 71
TABLE 8 CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY REGION, 2019–2026 (USD MILLION) 71
TABLE 9 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2019–2026 (USD MILLION) 72
TABLE 10 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2019–2026 (USD MILLION) 72
TABLE 11 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2019–2026 (USD MILLION) 73
6.4 PACKAGING, LABELING, AND BLINDING 73
6.4.1 RISING DEMAND FOR ADVANCED PACKAGING TO DRIVE
THIS MARKET SEGMENT. 73
TABLE 12 CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY REGION, 2019–2026 (USD MILLION) 74
TABLE 13 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR
PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY,
2019–2026 (USD MILLION) 74
TABLE 14 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2019–2026 (USD MILLION) 74
TABLE 15 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2019–2026 (USD MILLION) 75
6.5 MANUFACTURING 75
6.5.1 GROWING FOCUS OF COMPANIES ON INCREASING THEIR MANUFACTURING CAPACITIES TO DRIVE MARKET GROWTH 75
TABLE 16 CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES,
BY REGION, 2019–2026 (USD MILLION) 76
TABLE 17 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2019–2026 (USD MILLION) 76
TABLE 18 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2019–2026 (USD MILLION) 76
TABLE 19 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2019–2026 (USD MILLION) 77
6.6 COMPARATOR SOURCING 77
6.6.1 INTENSE MARKET COMPETITION, REGULATORY PRESSURE, INCREASING NUMBER OF CO-THERAPIES, AND THE RISING NUMBER OF CLINICAL TRIALS IN EMERGING COUNTRIES TO DRIVE GROWTH IN THIS SEGMENT 77
TABLE 20 CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY REGION, 2019–2026 (USD MILLION) 78
TABLE 21 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2019–2026 (USD MILLION) 78
TABLE 22 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2019–2026 (USD MILLION) 78
TABLE 23 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2019–2026 (USD MILLION) 79
6.7 OTHER SERVICES 79
TABLE 24 CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY REGION, 2019–2026 (USD MILLION) 80
TABLE 25 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY COUNTRY, 2019–2026 (USD MILLION) 80
TABLE 26 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES,
BY COUNTRY, 2019–2026 (USD MILLION) 80
TABLE 27 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES,
BY COUNTRY, 2019–2026 (USD MILLION) 81
7 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE 82
7.1 INTRODUCTION 83
TABLE 28 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019–2026 (USD MILLION) 83
7.2 PHASE III 83
7.2.1 SINCE PHASE III TRIALS INVOLVE A LARGE PATIENT POPULATION,
THE DEMAND FOR OUTSOURCING OF CLINICAL TRIAL SUPPLIES
IS HIGH IN THIS PHASE 83
TABLE 29 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS,
BY REGION, 2019–2026 (USD MILLION) 84
TABLE 30 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2019–2026 (USD MILLION) 84
TABLE 31 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2019–2026 (USD MILLION) 84
TABLE 32 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS,
BY COUNTRY, 2019–2026 (USD MILLION) 85
7.3 PHASE II 85
7.3.1 PHASE II CLINICAL TRIALS HELP IN UNDERSTANDING THE EFFECTIVENESS OF THE DRUG AND FURTHER EVALUATING ITS SAFETY—A KEY FACTOR
DRIVING MARKET GROWTH 85
TABLE 33 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS,
BY REGION, 2019–2026 (USD MILLION) 86
TABLE 34 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2019–2026 (USD MILLION) 86
TABLE 35 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2019–2026 (USD MILLION) 86
TABLE 36 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS,
BY COUNTRY, 2019–2026 (USD MILLION) 87
7.4 PHASE I 87
7.4.1 QUALITY OF CLINICAL TRIAL SUPPLIES AND LOGISTICS PLAY A VITAL ROLE IN PHASE I CLINICAL TRIALS 87
TABLE 37 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS,
BY REGION, 2019–2026 (USD MILLION) 87
TABLE 38 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2019–2026 (USD MILLION) 88
TABLE 39 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2019–2026 (USD MILLION) 88
TABLE 40 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS,
BY COUNTRY, 2019–2026 (USD MILLION) 88
7.5 PHASE IV 89
7.5.1 THESE STUDIES PRIMARILY ALLOW RESEARCHERS TO FIND AND OBSERVE THE LONG-TERM EFFECTS OF A PARTICULAR DRUG IN A CONSIDERABLY LARGER POOL OF PATIENTS—A KEY FACTOR DRIVING MARKET GROWTH 89
TABLE 41 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY REGION, 2019–2026 (USD MILLION) 89
TABLE 42 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2019–2026 (USD MILLION) 89
TABLE 43 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2019–2026 (USD MILLION) 90
TABLE 44 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS,
BY COUNTRY, 2019–2026 (USD MILLION) 90
7.6 BA/BE STUDIES 91
7.6.1 INCREASING PATENT EXPIRATION TO INCREASE THE DEMAND
FOR BA/BE STUDIES 91
TABLE 45 CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY REGION,
2019–2026 (USD MILLION) 91
TABLE 46 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY COUNTRY, 2019–2026 (USD MILLION) 91
TABLE 47 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES,
BY COUNTRY, 2019–2026 (USD MILLION) 92
TABLE 48 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES,
BY COUNTRY, 2019–2026 (USD MILLION) 92
8 CLINICAL TRIAL SUPPLIES MARKET, BY TYPE 93
8.1 INTRODUCTION 94
TABLE 49 CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019–2026 (USD MILLION) 94
8.2 SMALL-MOLECULE DRUGS 94
8.2.1 LOW COST OF DEVELOPING SMALL-MOLECULE DRUGS TO
DRIVE MARKET GROWTH 94
TABLE 50 CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS,
BY REGION, 2019–2026 (USD MILLION) 95
TABLE 51 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2019–2026 (USD MILLION) 95
TABLE 52 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2019–2026 (USD MILLION) 95
TABLE 53 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2019–2026 (USD MILLION) 96
8.3 BIOLOGIC DRUGS 96
8.3.1 BIOLOGIC DRUGS HAVE A RELATIVELY LOW RATE OF ATTRITION COMPARED TO SMALL-MOLECULE DRUGS—A KEY FACTOR DRIVING MARKET GROWTH 96
TABLE 54 CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY REGION, 2019–2026 (USD MILLION) 97
TABLE 55 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2019–2026 (USD MILLION) 97
TABLE 56 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS,
BY COUNTRY, 2019–2026 (USD MILLION) 97
TABLE 57 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS,
BY COUNTRY, 2019–2026 (USD MILLION) 98
8.4 MEDICAL DEVICES 98
8.4.1 INCREASING NUMBER OF TRIALS FOR MEDICAL DEVICES TO
DRIVE MARKET GROWTH 98
TABLE 58 CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY REGION, 2019–2026 (USD MILLION) 98
TABLE 59 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2019–2026 (USD MILLION) 99
TABLE 60 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES,
BY COUNTRY, 2019–2026 (USD MILLION) 99
TABLE 61 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES,
BY COUNTRY, 2019–2026 (USD MILLION) 99
9 CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA 100
9.1 INTRODUCTION 101
TABLE 62 CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 101
9.2 ONCOLOGY 101
9.2.1 GROWING STUDIES ON CANCER THERAPEUTICS TO DRIVE MARKET GROWTH 101
TABLE 63 CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY REGION,
2019–2026 (USD MILLION) 102
TABLE 64 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY,
BY COUNTRY, 2019–2026 (USD MILLION) 102
TABLE 65 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 103
TABLE 66 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 103
9.3 CNS & MENTAL DISORDERS 104
9.3.1 INCREASING CASES OF MENTAL DISORDERS TO DRIVE MARKET GROWTH 104
TABLE 67 CLINICAL TRIAL SUPPLIES MARKET FOR CNS & MENTAL DISORDERS,
BY REGION, 2019–2026 (USD MILLION) 104
TABLE 68 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CNS & MENTAL DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION) 104
TABLE 69 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR CNS & MENTAL DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION) 105
TABLE 70 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR CNS & MENTAL DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION) 105
9.4 CARDIOVASCULAR DISEASES 106
9.4.1 GROWING INVESTMENTS BY PHARMACEUTICAL COMPANIES FOR
CVD RESEARCH TO DRIVE GROWTH IN THIS MARKET SEGMENT 106
TABLE 71 CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR DISEASES,
BY REGION, 2019–2026 (USD MILLION) 106
TABLE 72 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 106
TABLE 73 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 107
TABLE 74 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 107
9.5 DIGESTIVE DISORDERS 108
9.5.1 INCREASING R&D FOR THE DEVELOPMENT OF EFFECTIVE DRUGS TO DRIVE THE DEMAND FOR CLINICAL TRIAL SUPPLIES FOR THIS THERAPEUTIC AREA 108
TABLE 75 CLINICAL TRIAL SUPPLIES MARKET FOR DIGESTIVE DISORDERS, BY REGION, 2019–2026 (USD MILLION) 108
TABLE 76 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR DIGESTIVE DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION) 108
TABLE 77 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR DIGESTIVE DISORDERS,
BY COUNTRY, 2019–2026 (USD MILLION) 109
TABLE 78 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR DIGESTIVE DISORDERS,
BY COUNTRY, 2019–2026 (USD MILLION) 109
9.6 INFECTIOUS DISEASES 110
9.6.1 EMERGENCE OF NEW INFECTIONS SUCH AS EBOLA, ZIKA, AND COVID-19 HAS ACCELERATED THE EFFORTS TO DEVELOP NEW DRUGS—THIS WILL DRIVE THE DEMAND FOR CLINICAL TRIAL SUPPLIES 110
TABLE 79 CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2019–2026 (USD MILLION) 110
TABLE 80 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 110
TABLE 81 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2019–2026 (USD MILLION) 111
TABLE 82 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2019–2026 (USD MILLION) 111
9.7 METABOLIC DISORDERS 112
9.7.1 INCREASING PREVALENCE OF DIABETES AND OTHER METABOLIC DISORDERS TO DRIVE MARKET GROWTH IN THE COMING YEARS 112
FIGURE 28 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES
FROM 2000 TO 2045 (IN MILLIONS) 112
TABLE 83 CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS,
BY REGION, 2019–2026 (USD MILLION) 112
TABLE 84 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION) 113
TABLE 85 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION) 113
TABLE 86 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS,
BY COUNTRY, 2019–2026 (USD MILLION) 113
9.8 BLOOD DISORDERS 114
9.8.1 GROWTH IN THE NUMBER OF HEMOPHILIA PATIENTS TO BOOST THE PRODUCTION OF MACROMOLECULES AND RECOMBINANT FACTORS 114
TABLE 87 CLINICAL TRIAL SUPPLIES MARKET FOR BLOOD DISORDERS, BY REGION, 2019–2026 (USD MILLION) 114
TABLE 88 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION) 114
TABLE 89 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR BLOOD DISORDERS,
BY COUNTRY, 2019–2026 (USD MILLION) 115
TABLE 90 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR BLOOD DISORDERS,
BY COUNTRY, 2019–2026 (USD MILLION) 115
9.9 IMMUNOLOGY 116
9.9.1 CONTINUOUS GROWTH IN CLINICAL STUDIES FOR IMMUNE SYSTEM DISEASES TO FUEL THE NEED FOR PROCURING CLINICAL TRIAL SUPPLIES 116
TABLE 91 CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY, BY REGION,
2019–2026 (USD MILLION) 116
TABLE 92 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY,
BY COUNTRY, 2019–2026 (USD MILLION) 116
TABLE 93 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY,
BY COUNTRY, 2019–2026 (USD MILLION) 117
TABLE 94 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 117
9.10 OTHER THERAPEUTIC AREAS 117
TABLE 95 CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS,
BY REGION, 2019–2026 (USD MILLION) 118
TABLE 96 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019–2026 (USD MILLION) 118
TABLE 97 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019–2026 (USD MILLION) 119
TABLE 98 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019–2026 (USD MILLION) 119
10 CLINICAL TRIAL SUPPLIES MARKET, BY END USER 120
10.1 INTRODUCTION 121
TABLE 99 CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2019–2026 (USD MILLION) 121
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 121
10.2.1 INCREASING R&D INVESTMENTS TO BOOST THE OUTSOURCING OF CLINICAL TRIAL SUPPLIES BY PHARMACEUTICAL AND BIOTECH COMPANIES 121
TABLE 100 CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019–2026 (USD MILLION) 122
TABLE 101 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 122
TABLE 102 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 122
TABLE 103 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 123
10.3 CONTRACT RESEARCH ORGANIZATIONS 123
10.3.1 INCREASING OUTSOURCING OF CLINICAL TRIALS TO DRIVE THE ADOPTION OF CLINICAL TRIAL SUPPLIES AMONG CROS 123
TABLE 104 CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2019–2026 (USD MILLION) 123
TABLE 105 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2019–2026 (USD MILLION) 124
TABLE 106 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2019–2026 (USD MILLION) 124
TABLE 107 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2019–2026 (USD MILLION) 124
10.4 MEDICAL DEVICE COMPANIES 125
10.4.1 INCREASING NUMBER OF TRIALS OF MEDICAL DEVICES TO
DRIVE MARKET GROWTH 125
TABLE 108 CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES,
BY REGION, 2019–2026 (USD MILLION) 125
TABLE 109 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 125
TABLE 110 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 126
TABLE 111 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 126
11 CLINICAL TRIAL SUPPLIES MARKET, BY REGION 127
11.1 INTRODUCTION 128
FIGURE 29 CLINICAL TRIAL SUPPLIES MARKET: GEOGRAPHICAL SNAPSHOT 128
TABLE 112 CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2019–2026 (USD MILLION) 129
11.2 NORTH AMERICA 129
FIGURE 30 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET SNAPSHOT 130
TABLE 113 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 130
TABLE 114 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2019–2026 (USD MILLION) 131
TABLE 115 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2019–2026 (USD MILLION) 131
TABLE 116 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2019–2026 (USD MILLION) 131
TABLE 117 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET,
BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 132
TABLE 118 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2019–2026 (USD MILLION) 132
11.2.1 US 132
11.2.1.1 Increasing R&D investments to drive market growth in the US 132
TABLE 119 US: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2019–2026 (USD MILLION) 133
TABLE 120 US: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2019–2026 (USD MILLION) 133
TABLE 121 US: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019–2026 (USD MILLION) 134
TABLE 122 US: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 134
TABLE 123 US: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2019–2026 (USD MILLION) 134
11.2.2 CANADA 135
11.2.2.1 Growing preference of pharmaceutical companies to conduct trials in Canada to favor market growth 135
TABLE 124 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2019–2026 (USD MILLION) 135
TABLE 125 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2019–2026 (USD MILLION) 136
TABLE 126 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2019–2026 (USD MILLION) 136
TABLE 127 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 136
TABLE 128 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2019–2026 (USD MILLION) 137
11.3 EUROPE 137
TABLE 129 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 138
TABLE 130 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2019–2026 (USD MILLION) 138
TABLE 131 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2019–2026 (USD MILLION) 138
TABLE 132 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2019–2026 (USD MILLION) 139
TABLE 133 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 139
TABLE 134 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2019–2026 (USD MILLION) 139

11.3.1 GERMANY 140
11.3.1.1 Growing number of sponsored trials to boost the demand for clinical trial supplies in Germany 140
TABLE 135 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2019–2026 (USD MILLION) 140
TABLE 136 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2019–2026 (USD MILLION) 141
TABLE 137 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2019–2026 (USD MILLION) 141
TABLE 138 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 141
TABLE 139 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2019–2026 (USD MILLION) 142
11.3.2 UK 142
11.3.2.1 Government policies leading to costlier R&D and supply chain restrictions post Brexit to limit market growth to a certain extent 142
TABLE 140 UK: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2019–2026 (USD MILLION) 143
TABLE 141 UK: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2019–2026 (USD MILLION) 143
TABLE 142 UK: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019–2026 (USD MILLION) 143
TABLE 143 UK: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 144
TABLE 144 UK: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2019–2026 (USD MILLION) 144
11.3.3 FRANCE 144
11.3.3.1 Presence of leading pharmaceutical companies to support market growth in France 144
TABLE 145 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2019–2026 (USD MILLION) 145
TABLE 146 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2019–2026 (USD MILLION) 145
TABLE 147 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2019–2026 (USD MILLION) 146
TABLE 148 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 146
TABLE 149 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2019–2026 (USD MILLION) 146
11.3.4 ITALY 147
11.3.4.1 Increasing number of drug approvals to drive the market for clinical trial supplies in Italy 147
TABLE 150 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2019–2026 (USD MILLION) 147
TABLE 151 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2019–2026 (USD MILLION) 147
TABLE 152 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2019–2026 (USD MILLION) 148
TABLE 153 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 148
TABLE 154 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2019–2026 (USD MILLION) 148
11.3.5 SPAIN 149
11.3.5.1 Increasing biologics production to support market growth in Spain 149
TABLE 155 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2019–2026 (USD MILLION) 149
TABLE 156 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2019–2026 (USD MILLION) 150
TABLE 157 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2019–2026 (USD MILLION) 150
TABLE 158 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 150
TABLE 159 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2019–2026 (USD MILLION) 151
11.3.6 SWITZERLAND 151
11.3.6.1 Growing R&D efforts to provide growth opportunities for the
clinical trial supplies market in Switzerland 151
TABLE 160 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2019–2026 (USD MILLION) 152
TABLE 161 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2019–2026 (USD MILLION) 152
TABLE 162 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2019–2026 (USD MILLION) 152
TABLE 163 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 153
TABLE 164 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2019–2026 (USD MILLION) 153
11.3.7 REST OF EUROPE 154
TABLE 165 ROE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2019–2026 (USD MILLION) 155
TABLE 166 ROE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2019–2026 (USD MILLION) 155
TABLE 167 ROE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2019–2026 (USD MILLION) 155
TABLE 168 ROE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 156
TABLE 169 ROE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2019–2026 (USD MILLION) 156
11.4 ASIA PACIFIC 157
FIGURE 31 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET SNAPSHOT 157
TABLE 170 APAC: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 158
TABLE 171 APAC: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2019–2026 (USD MILLION) 158
TABLE 172 APAC: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2019–2026 (USD MILLION) 158
TABLE 173 APAC: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2019–2026 (USD MILLION) 159
TABLE 174 APAC: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 159
TABLE 175 APAC: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2019–2026 (USD MILLION) 159
11.4.1 CHINA 160
11.4.1.1 Favorable government regulations are boosting the
market growth in China 160
TABLE 176 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2019–2026 (USD MILLION) 160
TABLE 177 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2019–2026 (USD MILLION) 161
TABLE 178 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2019–2026 (USD MILLION) 161
TABLE 179 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 161
TABLE 180 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2019–2026 (USD MILLION) 162
11.4.2 JAPAN 162
11.4.2.1 Government initiatives for drug innovation to support
market growth in Japan 162
TABLE 181 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2019–2026 (USD MILLION) 163
TABLE 182 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2019–2026 (USD MILLION) 163
TABLE 183 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2019–2026 (USD MILLION) 163
TABLE 184 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 164
TABLE 185 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2019–2026 (USD MILLION) 164
11.4.3 INDIA 164
11.4.3.1 Low manufacturing costs and a skilled workforce are factors attracting outsourcing and investment to India 164
TABLE 186 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2019–2026 (USD MILLION) 165
TABLE 187 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2019–2026 (USD MILLION) 165
TABLE 188 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2019–2026 (USD MILLION) 166
TABLE 189 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 166
TABLE 190 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2019–2026 (USD MILLION) 166
11.4.4 AUSTRALIA 167
11.4.4.1 Australia has many research institutes conducting clinical trials—this is a key factor boosting the growth of the market 167
TABLE 191 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2019–2026 (USD MILLION) 167
TABLE 192 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2019–2026 (USD MILLION) 167
TABLE 193 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2019–2026 (USD MILLION) 168
TABLE 194 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 168
TABLE 195 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2019–2026 (USD MILLION) 168
11.4.5 SOUTH KOREA 169
11.4.5.1 Government investments are a key contributor to market growth in South Korea 169
TABLE 196 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2019–2026 (USD MILLION) 169
TABLE 197 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2019–2026 (USD MILLION) 170
TABLE 198 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2019–2026 (USD MILLION) 170
TABLE 199 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 170
TABLE 200 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2019–2026 (USD MILLION) 171
11.4.6 SINGAPORE 171
11.4.6.1 Presence of world-class infrastructure to drive market
growth in Singapore 171
TABLE 201 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2019–2026 (USD MILLION) 171
TABLE 202 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2019–2026 (USD MILLION) 172
TABLE 203 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2019–2026 (USD MILLION) 172
TABLE 204 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 172
TABLE 205 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2019–2026 (USD MILLION) 173
11.4.7 REST OF ASIA PACIFIC 173
TABLE 206 ROAPAC: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2019–2026 (USD MILLION) 173
TABLE 207 ROAPAC: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2019–2026 (USD MILLION) 174
TABLE 208 ROAPAC: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2019–2026 (USD MILLION) 174
TABLE 209 ROAPAC: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2019–2026 (USD MILLION) 174
TABLE 210 ROAPAC: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2019–2026 (USD MILLION) 175 1 INTRODUCTION 33 1.1 OBJECTIVES OF THE STUDY 33 1.2 MARKET DEFINITION 33 1.2.1 INCLUSIONS & EXCLUSIONS 34 1.3 MARKET SCOPE 35 1.3.1 MARKETS COVERED 35 1.3.2 YEARS CONSIDERED FOR THE STUDY 36 1.4 CURRENCY 36 1.5 LIMITATIONS 36 1.6 STAKEHOLDERS 36 1.7 SUMMARY OF CHANGES 37 2 RESEARCH METHODOLOGY 38 2.1 RESEARCH APPROACH 38 FIGURE 1 RESEARCH DESIGN 38 2.1.1 SECONDARY DATA 38 2.1.2 PRIMARY DATA 39 FIGURE 2 BREAKDOWN OF PRIMARIES: CLINICAL TRIAL SUPPLIES MARKET 40 2.1.3 MARKET DATA ESTIMATION & TRIANGULATION 41 FIGURE 3 DATA TRIANGULATION METHODOLOGY 41 2.2 MARKET ESTIMATION METHODOLOGY 42 FIGURE 4 MARKET SIZE ESTIMATION APPROACH: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH) 42 FIGURE 5 MARKET SIZE ESTIMATION APPROACH: PARENT MARKET (TOP-DOWN APPROACH) 42 FIGURE 6 CLINICAL TRIAL SUPPLIES MARKET: FINAL MARKET SIZE (USD BILLION) 43 2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST 44 FIGURE 7 GROWTH RATE ASSUMPTION BASED ON MARKET DYNAMICS 44 FIGURE 8 FINAL CAGR PROJECTIONS (2021−2026) 44 2.4 INSIGHTS FROM PRIMARIES 45 FIGURE 9 MARKET VALIDATION FROM PRIMARY EXPERTS 45 2.5 RESEARCH ASSUMPTIONS 45 2.6 RISK ASSESSMENT 45 TABLE 1 RISK ASSESSMENT 45 3 EXECUTIVE SUMMARY 46 FIGURE 10 CLINICAL TRIAL SUPPLIES MARKET SHARE, BY TYPE, 2020 VS. 2026 46 FIGURE 11 CLINICAL TRIAL SUPPLIES MARKET SHARE, BY SERVICE, 2020 47 FIGURE 12 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2021 VS. 2026 47 FIGURE 13 CLINICAL TRIAL SUPPLIES MARKET SHARE, BY THERAPEUTIC AREA, 2020 48 FIGURE 14 CLINICAL TRIAL SUPPLIES MARKET SHARE, BY END USER, 2020 48 FIGURE 15 GEOGRAPHICAL SNAPSHOT OF THE CLINICAL TRIAL SUPPLIES MARKET 49 4 PREMIUM INSIGHTS 50 4.1 CLINICAL TRIAL SUPPLIES MARKET OVERVIEW 50 FIGURE 16 INCREASING R&D INVESTMENTS TO DRIVE MARKET GROWTH 50 4.2 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET SHARE, BY TYPE & COUNTRY (2020) 51 FIGURE 17 SMALL-MOLECULE DRUGS ACCOUNTED FOR THE LARGEST SHARE OF THE CLINICAL TRIAL SUPPLIES MARKET IN NORTH AMERICA 51 4.3 CLINICAL TRIAL SUPPLIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 52 FIGURE 18 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH IN THE CLINICAL TRIAL SUPPLIES MARKET FROM 2021 TO 2026 52 5 MARKET OVERVIEW 53 5.1 INTRODUCTION 53 5.2 MARKET DYNAMICS 53 FIGURE 19 CLINICAL TRIAL SUPPLIES MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES 53 5.3 IMPACT ANALYSIS 54 5.3.1 DRIVERS 54 5.3.1.1 Increasing R&D expenditure of pharmaceutical and biopharmaceutical companies 54 TABLE 2 R&D EXPENDITURE OF LEADING PHARMACEUTICAL COMPANIES IN 2019 54 FIGURE 20 NUMBER OF PHARMA COMPANIES WITH ACTIVE DRUG PIPELINE PROJECTS (2010–2020) 55 FIGURE 21 GLOBAL R&D SPENDING (2016–2020) 55 5.3.1.2 Increasing number of registered clinical trials 56 FIGURE 22 NUMBER OF CLINICAL TRIALS IN THE LAST 10 YEARS 56 5.3.1.3 Increasing decentralization of clinical trials 56 5.3.2 RESTRAINTS 56 5.3.2.1 High cost of drug development 56 5.3.3 OPPORTUNITIES 57 5.3.3.1 Emerging markets 57 5.4 RANGES/SCENARIOS 57 FIGURE 23 DEPENDING ON HOW UNCERTAINTIES UNFOLD, WE SEE A SPECTRUM OF SCENARIOS FOR THE CLINICAL TRIAL SUPPLIES MARKET 57 5.5 COVID-19 IMPACT ANALYSIS 58 FIGURE 24 NUMBER OF CLINICAL TRIALS, BY PHASE (2020–2021) 58 FIGURE 25 NUMBER OF CLINICAL TRIALS, BY COUNTRY 58 5.6 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 59 FIGURE 26 PRE-COVID-19 VS. POST-COVID-19 SCENARIO 59 5.7 VALUE CHAIN ANALYSIS 60 FIGURE 27 VALUE CHAIN ANALYSIS OF THE CLINICAL TRIAL SUPPLIES MARKET 60 5.8 ECOSYSTEM/MARKET MAP 60 5.9 SUPPLY CHAIN 61 5.10 PORTER’S FIVE FORCES ANALYSIS 62 5.10.1 PORTER’S 5 FORCES IMPACT ON THE CLINICAL TRIAL SUPPLIES MARKET 62 5.10.1.1 Threat from new entrants 62 5.10.1.2 Threat from substitutes 63 5.10.1.3 Bargaining power of suppliers 63 5.10.1.4 Bargaining power of buyers 63 5.10.1.5 Degree of competition 63 5.11 REGULATORY LANDSCAPE 64 5.11.1 INTRODUCTION 64 6 CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE 68 6.1 INTRODUCTION 69 TABLE 3 CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION) 69 6.2 LOGISTICS & DISTRIBUTION 69 6.2.1 INCREASING COMPLEXITY, EVOLVING TREATMENT PROTOCOLS, TECHNOLOGICAL ADVANCEMENTS, AND DATA SECURITY CHALLENGES TO DRIVE THE DEMAND FOR LOGISTICS & DISTRIBUTION SERVICES 69 TABLE 4 CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY REGION, 2019–2026 (USD MILLION) 70 TABLE 5 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2019–2026 (USD MILLION) 70 TABLE 6 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2019–2026 (USD MILLION) 70 TABLE 7 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2019–2026 (USD MILLION) 71 6.3 STORAGE & RETENTION 71 6.3.1 GROWING DEMAND FOR DIRECT-TO-PATIENT AND DIRECT-TO-SITE SERVICES TO DRIVE GROWTH IN THE STORAGE & RETENTION SERVICES MARKET SEGMENT 71 TABLE 8 CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY REGION, 2019–2026 (USD MILLION) 71 TABLE 9 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2019–2026 (USD MILLION) 72 TABLE 10 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2019–2026 (USD MILLION) 72 TABLE 11 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2019–2026 (USD MILLION) 73 6.4 PACKAGING, LABELING, AND BLINDING 73 6.4.1 RISING DEMAND FOR ADVANCED PACKAGING TO DRIVE THIS MARKET SEGMENT. 73 TABLE 12 CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY REGION, 2019–2026 (USD MILLION) 74 TABLE 13 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2019–2026 (USD MILLION) 74 TABLE 14 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2019–2026 (USD MILLION) 74 TABLE 15 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2019–2026 (USD MILLION) 75 6.5 MANUFACTURING 75 6.5.1 GROWING FOCUS OF COMPANIES ON INCREASING THEIR MANUFACTURING CAPACITIES TO DRIVE MARKET GROWTH 75 TABLE 16 CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY REGION, 2019–2026 (USD MILLION) 76 TABLE 17 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2019–2026 (USD MILLION) 76 TABLE 18 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2019–2026 (USD MILLION) 76 TABLE 19 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2019–2026 (USD MILLION) 77 6.6 COMPARATOR SOURCING 77 6.6.1 INTENSE MARKET COMPETITION, REGULATORY PRESSURE, INCREASING NUMBER OF CO-THERAPIES, AND THE RISING NUMBER OF CLINICAL TRIALS IN EMERGING COUNTRIES TO DRIVE GROWTH IN THIS SEGMENT 77 TABLE 20 CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY REGION, 2019–2026 (USD MILLION) 78 TABLE 21 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2019–2026 (USD MILLION) 78 TABLE 22 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2019–2026 (USD MILLION) 78 TABLE 23 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2019–2026 (USD MILLION) 79 6.7 OTHER SERVICES 79 TABLE 24 CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY REGION, 2019–2026 (USD MILLION) 80 TABLE 25 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY COUNTRY, 2019–2026 (USD MILLION) 80 TABLE 26 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY COUNTRY, 2019–2026 (USD MILLION) 80 TABLE 27 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY COUNTRY, 2019–2026 (USD MILLION) 81 7 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE 82 7.1 INTRODUCTION 83 TABLE 28 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019–2026 (USD MILLION) 83 7.2 PHASE III 83 7.2.1 SINCE PHASE III TRIALS INVOLVE A LARGE PATIENT POPULATION, THE DEMAND FOR OUTSOURCING OF CLINICAL TRIAL SUPPLIES IS HIGH IN THIS PHASE 83 TABLE 29 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS, BY REGION, 2019–2026 (USD MILLION) 84 TABLE 30 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2019–2026 (USD MILLION) 84 TABLE 31 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2019–2026 (USD MILLION) 84 TABLE 32 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2019–2026 (USD MILLION) 85 7.3 PHASE II 85 7.3.1 PHASE II CLINICAL TRIALS HELP IN UNDERSTANDING THE EFFECTIVENESS OF THE DRUG AND FURTHER EVALUATING ITS SAFETY—A KEY FACTOR DRIVING MARKET GROWTH 85 TABLE 33 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS, BY REGION, 2019–2026 (USD MILLION) 86 TABLE 34 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2019–2026 (USD MILLION) 86 TABLE 35 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2019–2026 (USD MILLION) 86 TABLE 36 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2019–2026 (USD MILLION) 87 7.4 PHASE I 87 7.4.1 QUALITY OF CLINICAL TRIAL SUPPLIES AND LOGISTICS PLAY A VITAL ROLE IN PHASE I CLINICAL TRIALS 87 TABLE 37 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS, BY REGION, 2019–2026 (USD MILLION) 87 TABLE 38 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2019–2026 (USD MILLION) 88 TABLE 39 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2019–2026 (USD MILLION) 88 TABLE 40 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2019–2026 (USD MILLION) 88 7.5 PHASE IV 89 7.5.1 THESE STUDIES PRIMARILY ALLOW RESEARCHERS TO FIND AND OBSERVE THE LONG-TERM EFFECTS OF A PARTICULAR DRUG IN A CONSIDERABLY LARGER POOL OF PATIENTS—A KEY FACTOR DRIVING MARKET GROWTH 89 TABLE 41 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY REGION, 2019–2026 (USD MILLION) 89 TABLE 42 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2019–2026 (USD MILLION) 89 TABLE 43 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2019–2026 (USD MILLION) 90 TABLE 44 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV CLINICAL TRIALS, BY COUNTRY, 2019–2026 (USD MILLION) 90 7.6 BA/BE STUDIES 91 7.6.1 INCREASING PATENT EXPIRATION TO INCREASE THE DEMAND FOR BA/BE STUDIES 91 TABLE 45 CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY REGION, 2019–2026 (USD MILLION) 91 TABLE 46 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY COUNTRY, 2019–2026 (USD MILLION) 91 TABLE 47 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY COUNTRY, 2019–2026 (USD MILLION) 92 TABLE 48 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR BA/BE STUDIES, BY COUNTRY, 2019–2026 (USD MILLION) 92 8 CLINICAL TRIAL SUPPLIES MARKET, BY TYPE 93 8.1 INTRODUCTION 94 TABLE 49 CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019–2026 (USD MILLION) 94 8.2 SMALL-MOLECULE DRUGS 94 8.2.1 LOW COST OF DEVELOPING SMALL-MOLECULE DRUGS TO DRIVE MARKET GROWTH 94 TABLE 50 CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY REGION, 2019–2026 (USD MILLION) 95 TABLE 51 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2019–2026 (USD MILLION) 95 TABLE 52 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2019–2026 (USD MILLION) 95 TABLE 53 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2019–2026 (USD MILLION) 96 8.3 BIOLOGIC DRUGS 96 8.3.1 BIOLOGIC DRUGS HAVE A RELATIVELY LOW RATE OF ATTRITION COMPARED TO SMALL-MOLECULE DRUGS—A KEY FACTOR DRIVING MARKET GROWTH 96 TABLE 54 CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY REGION, 2019–2026 (USD MILLION) 97 TABLE 55 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2019–2026 (USD MILLION) 97 TABLE 56 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2019–2026 (USD MILLION) 97 TABLE 57 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2019–2026 (USD MILLION) 98 8.4 MEDICAL DEVICES 98 8.4.1 INCREASING NUMBER OF TRIALS FOR MEDICAL DEVICES TO DRIVE MARKET GROWTH 98 TABLE 58 CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY REGION, 2019–2026 (USD MILLION) 98 TABLE 59 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2019–2026 (USD MILLION) 99 TABLE 60 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2019–2026 (USD MILLION) 99 TABLE 61 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2019–2026 (USD MILLION) 99 9 CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA 100 9.1 INTRODUCTION 101 TABLE 62 CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 101 9.2 ONCOLOGY 101 9.2.1 GROWING STUDIES ON CANCER THERAPEUTICS TO DRIVE MARKET GROWTH 101 TABLE 63 CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY REGION, 2019–2026 (USD MILLION) 102 TABLE 64 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 102 TABLE 65 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 103 TABLE 66 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 103 9.3 CNS & MENTAL DISORDERS 104 9.3.1 INCREASING CASES OF MENTAL DISORDERS TO DRIVE MARKET GROWTH 104 TABLE 67 CLINICAL TRIAL SUPPLIES MARKET FOR CNS & MENTAL DISORDERS, BY REGION, 2019–2026 (USD MILLION) 104 TABLE 68 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CNS & MENTAL DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION) 104 TABLE 69 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR CNS & MENTAL DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION) 105 TABLE 70 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR CNS & MENTAL DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION) 105 9.4 CARDIOVASCULAR DISEASES 106 9.4.1 GROWING INVESTMENTS BY PHARMACEUTICAL COMPANIES FOR CVD RESEARCH TO DRIVE GROWTH IN THIS MARKET SEGMENT 106 TABLE 71 CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2019–2026 (USD MILLION) 106 TABLE 72 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 106 TABLE 73 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 107 TABLE 74 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 107 9.5 DIGESTIVE DISORDERS 108 9.5.1 INCREASING R&D FOR THE DEVELOPMENT OF EFFECTIVE DRUGS TO DRIVE THE DEMAND FOR CLINICAL TRIAL SUPPLIES FOR THIS THERAPEUTIC AREA 108 TABLE 75 CLINICAL TRIAL SUPPLIES MARKET FOR DIGESTIVE DISORDERS, BY REGION, 2019–2026 (USD MILLION) 108 TABLE 76 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR DIGESTIVE DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION) 108 TABLE 77 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR DIGESTIVE DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION) 109 TABLE 78 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR DIGESTIVE DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION) 109 9.6 INFECTIOUS DISEASES 110 9.6.1 EMERGENCE OF NEW INFECTIONS SUCH AS EBOLA, ZIKA, AND COVID-19 HAS ACCELERATED THE EFFORTS TO DEVELOP NEW DRUGS—THIS WILL DRIVE THE DEMAND FOR CLINICAL TRIAL SUPPLIES 110 TABLE 79 CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2019–2026 (USD MILLION) 110 TABLE 80 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 110 TABLE 81 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 111 TABLE 82 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 111 9.7 METABOLIC DISORDERS 112 9.7.1 INCREASING PREVALENCE OF DIABETES AND OTHER METABOLIC DISORDERS TO DRIVE MARKET GROWTH IN THE COMING YEARS 112 FIGURE 28 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES FROM 2000 TO 2045 (IN MILLIONS) 112 TABLE 83 CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS, BY REGION, 2019–2026 (USD MILLION) 112 TABLE 84 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION) 113 TABLE 85 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION) 113 TABLE 86 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION) 113 9.8 BLOOD DISORDERS 114 9.8.1 GROWTH IN THE NUMBER OF HEMOPHILIA PATIENTS TO BOOST THE PRODUCTION OF MACROMOLECULES AND RECOMBINANT FACTORS 114 TABLE 87 CLINICAL TRIAL SUPPLIES MARKET FOR BLOOD DISORDERS, BY REGION, 2019–2026 (USD MILLION) 114 TABLE 88 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION) 114 TABLE 89 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION) 115 TABLE 90 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION) 115 9.9 IMMUNOLOGY 116 9.9.1 CONTINUOUS GROWTH IN CLINICAL STUDIES FOR IMMUNE SYSTEM DISEASES TO FUEL THE NEED FOR PROCURING CLINICAL TRIAL SUPPLIES 116 TABLE 91 CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY, BY REGION, 2019–2026 (USD MILLION) 116 TABLE 92 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 116 TABLE 93 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 117 TABLE 94 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 117 9.10 OTHER THERAPEUTIC AREAS 117 TABLE 95 CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2019–2026 (USD MILLION) 118 TABLE 96 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019–2026 (USD MILLION) 118 TABLE 97 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019–2026 (USD MILLION) 119 TABLE 98 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019–2026 (USD MILLION) 119 10 CLINICAL TRIAL SUPPLIES MARKET, BY END USER 120 10.1 INTRODUCTION 121 TABLE 99 CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019–2026 (USD MILLION) 121 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 121 10.2.1 INCREASING R&D INVESTMENTS TO BOOST THE OUTSOURCING OF CLINICAL TRIAL SUPPLIES BY PHARMACEUTICAL AND BIOTECH COMPANIES 121 TABLE 100 CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019–2026 (USD MILLION) 122 TABLE 101 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 122 TABLE 102 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 122 TABLE 103 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 123 10.3 CONTRACT RESEARCH ORGANIZATIONS 123 10.3.1 INCREASING OUTSOURCING OF CLINICAL TRIALS TO DRIVE THE ADOPTION OF CLINICAL TRIAL SUPPLIES AMONG CROS 123 TABLE 104 CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2019–2026 (USD MILLION) 123 TABLE 105 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2019–2026 (USD MILLION) 124 TABLE 106 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2019–2026 (USD MILLION) 124 TABLE 107 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2019–2026 (USD MILLION) 124 10.4 MEDICAL DEVICE COMPANIES 125 10.4.1 INCREASING NUMBER OF TRIALS OF MEDICAL DEVICES TO DRIVE MARKET GROWTH 125 TABLE 108 CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2019–2026 (USD MILLION) 125 TABLE 109 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 125 TABLE 110 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 126 TABLE 111 APAC: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 126 11 CLINICAL TRIAL SUPPLIES MARKET, BY REGION 127 11.1 INTRODUCTION 128 FIGURE 29 CLINICAL TRIAL SUPPLIES MARKET: GEOGRAPHICAL SNAPSHOT 128 TABLE 112 CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2019–2026 (USD MILLION) 129 11.2 NORTH AMERICA 129 FIGURE 30 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET SNAPSHOT 130 TABLE 113 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 130 TABLE 114 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION) 131 TABLE 115 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019–2026 (USD MILLION) 131 TABLE 116 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019–2026 (USD MILLION) 131 TABLE 117 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 132 TABLE 118 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019–2026 (USD MILLION) 132 11.2.1 US 132 11.2.1.1 Increasing R&D investments to drive market growth in the US 132 TABLE 119 US: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION) 133 TABLE 120 US: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019–2026 (USD MILLION) 133 TABLE 121 US: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019–2026 (USD MILLION) 134 TABLE 122 US: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 134 TABLE 123 US: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019–2026 (USD MILLION) 134 11.2.2 CANADA 135 11.2.2.1 Growing preference of pharmaceutical companies to conduct trials in Canada to favor market growth 135 TABLE 124 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION) 135 TABLE 125 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019–2026 (USD MILLION) 136 TABLE 126 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019–2026 (USD MILLION) 136 TABLE 127 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 136 TABLE 128 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019–2026 (USD MILLION) 137 11.3 EUROPE 137 TABLE 129 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 138 TABLE 130 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION) 138 TABLE 131 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019–2026 (USD MILLION) 138 TABLE 132 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019–2026 (USD MILLION) 139 TABLE 133 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 139 TABLE 134 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019–2026 (USD MILLION) 139 11.3.1 GERMANY 140 11.3.1.1 Growing number of sponsored trials to boost the demand for clinical trial supplies in Germany 140 TABLE 135 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION) 140 TABLE 136 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019–2026 (USD MILLION) 141 TABLE 137 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019–2026 (USD MILLION) 141 TABLE 138 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 141 TABLE 139 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019–2026 (USD MILLION) 142 11.3.2 UK 142 11.3.2.1 Government policies leading to costlier R&D and supply chain restrictions post Brexit to limit market growth to a certain extent 142 TABLE 140 UK: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION) 143 TABLE 141 UK: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019–2026 (USD MILLION) 143 TABLE 142 UK: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019–2026 (USD MILLION) 143 TABLE 143 UK: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 144 TABLE 144 UK: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019–2026 (USD MILLION) 144 11.3.3 FRANCE 144 11.3.3.1 Presence of leading pharmaceutical companies to support market growth in France 144 TABLE 145 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION) 145 TABLE 146 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019–2026 (USD MILLION) 145 TABLE 147 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019–2026 (USD MILLION) 146 TABLE 148 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 146 TABLE 149 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019–2026 (USD MILLION) 146 11.3.4 ITALY 147 11.3.4.1 Increasing number of drug approvals to drive the market for clinical trial supplies in Italy 147 TABLE 150 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION) 147 TABLE 151 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019–2026 (USD MILLION) 147 TABLE 152 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019–2026 (USD MILLION) 148 TABLE 153 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 148 TABLE 154 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019–2026 (USD MILLION) 148 11.3.5 SPAIN 149 11.3.5.1 Increasing biologics production to support market growth in Spain 149 TABLE 155 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION) 149 TABLE 156 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019–2026 (USD MILLION) 150 TABLE 157 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019–2026 (USD MILLION) 150 TABLE 158 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 150 TABLE 159 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019–2026 (USD MILLION) 151 11.3.6 SWITZERLAND 151 11.3.6.1 Growing R&D efforts to provide growth opportunities for the clinical trial supplies market in Switzerland 151 TABLE 160 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION) 152 TABLE 161 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019–2026 (USD MILLION) 152 TABLE 162 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019–2026 (USD MILLION) 152 TABLE 163 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 153 TABLE 164 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019–2026 (USD MILLION) 153 11.3.7 REST OF EUROPE 154 TABLE 165 ROE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION) 155 TABLE 166 ROE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019–2026 (USD MILLION) 155 TABLE 167 ROE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019–2026 (USD MILLION) 155 TABLE 168 ROE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 156 TABLE 169 ROE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019–2026 (USD MILLION) 156 11.4 ASIA PACIFIC 157 FIGURE 31 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET SNAPSHOT 157 TABLE 170 APAC: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 158 TABLE 171 APAC: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION) 158 TABLE 172 APAC: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019–2026 (USD MILLION) 158 TABLE 173 APAC: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019–2026 (USD MILLION) 159 TABLE 174 APAC: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 159 TABLE 175 APAC: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019–2026 (USD MILLION) 159 11.4.1 CHINA 160 11.4.1.1 Favorable government regulations are boosting the market growth in China 160 TABLE 176 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION) 160 TABLE 177 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019–2026 (USD MILLION) 161 TABLE 178 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019–2026 (USD MILLION) 161 TABLE 179 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 161 TABLE 180 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019–2026 (USD MILLION) 162 11.4.2 JAPAN 162 11.4.2.1 Government initiatives for drug innovation to support market growth in Japan 162 TABLE 181 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION) 163 TABLE 182 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019–2026 (USD MILLION) 163 TABLE 183 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019–2026 (USD MILLION) 163 TABLE 184 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 164 TABLE 185 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019–2026 (USD MILLION) 164 11.4.3 INDIA 164 11.4.3.1 Low manufacturing costs and a skilled workforce are factors attracting outsourcing and investment to India 164 TABLE 186 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION) 165 TABLE 187 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019–2026 (USD MILLION) 165 TABLE 188 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019–2026 (USD MILLION) 166 TABLE 189 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 166 TABLE 190 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019–2026 (USD MILLION) 166 11.4.4 AUSTRALIA 167 11.4.4.1 Australia has many research institutes conducting clinical trials—this is a key factor boosting the growth of the market 167 TABLE 191 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION) 167 TABLE 192 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019–2026 (USD MILLION) 167 TABLE 193 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019–2026 (USD MILLION) 168 TABLE 194 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 168 TABLE 195 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019–2026 (USD MILLION) 168 11.4.5 SOUTH KOREA 169 11.4.5.1 Government investments are a key contributor to market growth in South Korea 169 TABLE 196 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION) 169 TABLE 197 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019–2026 (USD MILLION) 170 TABLE 198 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019–2026 (USD MILLION) 170 TABLE 199 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 170 TABLE 200 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019–2026 (USD MILLION) 171 11.4.6 SINGAPORE 171 11.4.6.1 Presence of world-class infrastructure to drive market growth in Singapore 171 TABLE 201 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION) 171 TABLE 202 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019–2026 (USD MILLION) 172 TABLE 203 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019–2026 (USD MILLION) 172 TABLE 204 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 172 TABLE 205 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019–2026 (USD MILLION) 173 11.4.7 REST OF ASIA PACIFIC 173 TABLE 206 ROAPAC: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2019–2026 (USD MILLION) 173 TABLE 207 ROAPAC: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2019–2026 (USD MILLION) 174 TABLE 208 ROAPAC: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2019–2026 (USD MILLION) 174 TABLE 209 ROAPAC: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 174 TABLE 210 ROAPAC: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2019–2026 (USD MILLION) 175

Pharmaceutical Packaging Equipment Market by Product (Aseptic Packaging, Blister, Strip, Bottle, Tube, Carton, Case Packer, Wrapping Machine, Palletiz...

Publisher: MarketsandMarkets

# of Pages: 378

Publication Date: March, 2022

Price: $4,950 / User License

1 INTRODUCTION 39
1.1 OBJECTIVES OF THE STUDY 39
1.2 MARKET DEFINITION 40
1.2.1 INCLUSIONS AND EXCLUSIONS 40
1.3 MARKET SCOPE 41
1.3.1 MARKETS COVERED 41
FIGURE 1 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET SEGMENTATION 41
1.3.2 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET: BY REGION 42
1.4 YEARS CONSIDERED FOR THE STUDY 42
1.5 CURRENCY 43
TABLE 1 STANDARD CURRENCY CONVERSION RATES 43
1.6 LIMITATIONS 43
1.7 STAKEHOLDERS 43
1.8 SUMMARY OF CHANGES 44
2 RESEARCH METHODOLOGY 45
2.1 RESEARCH DATA 45
FIGURE 2 RESEARCH DESIGN 45
2.1.1 SECONDARY DATA 46
2.1.1.1 Key data from secondary sources 47
2.1.2 PRIMARY DATA 48
FIGURE 3 PRIMARY SOURCES 48
2.1.2.1 Key data from primary sources 49
2.1.2.2 Key industry insights 50
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS 50
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 51
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 51
2.2 MARKET SIZE ESTIMATION 52
FIGURE 7 SUPPLY SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 52
FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION: SYNTEGON TECHNOLOGY GMBH 53
FIGURE 9 SUPPLY SIDE MARKET SIZE ESTIMATION: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET (2020) 54
FIGURE 10 APPROACH 3: BASED ON SOURCE, BY REGION (2022) 55
FIGURE 11 TOP-DOWN APPROACH 55
FIGURE 12 CAGR PROJECTIONS FROM DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES ANALYSIS (2022–2027) 57
FIGURE 13 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS 57
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 58
FIGURE 14 DATA TRIANGULATION METHODOLOGY 59
2.4 MARKET SHARE ESTIMATION 60
2.5 ASSUMPTIONS FOR THE STUDY 60
2.6 LIMITATIONS 60
2.6.1 METHODOLOGY-RELATED LIMITATIONS 61
2.7 RISK ASSESSMENT 61
TABLE 2 RISK ASSESSMENT: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET 61
2.8 ASSESSMENT OF COVID-19 IMPACT ON ECONOMIC SCENARIO 61
3 EXECUTIVE SUMMARY 63
FIGURE 15 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT,
2022 VS. 2027 (USD MILLION) 63
FIGURE 16 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE,
2022 VS. 2027 (USD MILLION) 64
FIGURE 17 GEOGRAPHICAL SNAPSHOT OF PHARMACEUTICAL PACKAGING EQUIPMENT MARKET 65
4 PREMIUM INSIGHTS 66
4.1 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET OVERVIEW 66
FIGURE 18 RISING NEED FOR FLEXIBLE AND INTEGRATED PACKAGING EQUIPMENT TO DRIVE MARKET GROWTH 66
4.2 ASIA PACIFIC: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY PRODUCT AND COUNTRY (2021) 67
FIGURE 19 PRIMARY PACKAGING EQUIPMENT SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF APAC MARKET IN 2021 67
4.3 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 68
FIGURE 20 CHINA TO REGISTER THE HIGHEST GROWTH DURING FORECAST PERIOD 68
4.4 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, REGIONAL MIX, 2022−2027 68
FIGURE 21 EUROPE TO DOMINATE PHARMACEUTICAL PACKAGING EQUIPMENT MARKET 68
4.5 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET: DEVELOPING VS. DEVELOPED MARKETS 69
FIGURE 22 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING
FORECAST PERIOD 69
5 MARKET OVERVIEW 70
5.1 INTRODUCTION 70
5.2 MARKET DYNAMICS 70
FIGURE 23 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 70
5.2.1 DRIVERS 71
5.2.1.1 High growth in generics & biopharmaceuticals markets 71
FIGURE 24 SALES OF GENERIC DRUGS GLOBALLY, 2006–2020 (USD BILLION) 71
FIGURE 25 GLOBAL PHARMACEUTICALS MARKET (USD BILLION) 71
TABLE 3 LIST OF OFF-PATENT DRUGS, 2015−2029 72
5.2.1.2 Growing need for flexible and integrated packaging equipment 73
5.2.1.3 Increase in offshore pharmaceutical manufacturing 73
FIGURE 26 PHARMACEUTICAL IMPORTS AND EXPORTS, BY COUNTRY,
2020 (USD BILLION) 74
5.2.1.4 Growing contract manufacturing of pharmaceutical products 74
5.2.1.5 Introduction of regulatory standards on packaging and stringent norms against counterfeit products 74
TABLE 4 KEY REGULATIONS & STANDARDS GOVERNING PHARMACEUTICAL PACKAGING EQUIPMENT 75
5.2.1.6 Innovation in pharmaceutical packaging and delivery system 75
5.2.1.7 Growth in OTC drug sales and regulations to reduce OTC counterfeit 76
FIGURE 27 GLOBAL OTC PHARMACEUTICALS MARKET SIZE, 2020 (USD BILLION) 76
5.2.2 RESTRAINTS 76
5.2.2.1 Growing preference for refurbished equipment 76
5.2.3 OPPORTUNITIES 77
5.2.3.1 Growth of pharmaceutical manufacturing in emerging economies 77
5.2.3.2 Rising demand for automated packaging 77
5.2.3.3 Change in medication systems to self-medication and self-care 78
5.2.3.4 Increasing pharmaceutical R&D investments 78
FIGURE 28 PHARMACEUTICAL & BIOPHARMACEUTICAL R&D EXPENDITURE,
2017–2024 79
FIGURE 29 NUMBER OF REGISTERED STUDIES, 2001-2022
(AS OF FEBRUARY 22, 2022) 79
FIGURE 30 NUMBER OF PIPELINE DRUGS, BY COMPANY, 2019 80
5.2.4 CHALLENGES 80
5.2.4.1 Growth in personalized and precision medicine supply chain 80
5.2.4.2 Uncertainties in regulations and standards of pharmaceutical packaging process 81
5.3 TECHNOLOGICAL ROADMAP 82
FIGURE 31 PHARMACEUTICAL PACKAGING EQUIPMENT: TECHNOLOGICAL ROADMAP 82
5.4 INDUSTRY TRENDS 83
FIGURE 32 MAJOR TRENDS IN PHARMACEUTICAL PACKAGING EQUIPMENT MARKET 83
5.4.1 DEVELOPMENT OF PRODUCTION LINES FOR SMALL BATCH SIZES AND RESEARCH PURPOSES 83
5.4.2 AUTOMATION AND INTEGRATION OF PACKAGING EQUIPMENT 84
5.4.3 GROWING FOCUS ON LABELING AND SERIALIZATION FOR ANTI-COUNTERFEITING OF DRUGS 85
5.4.4 GROWING DEMAND FOR ASEPTIC FILLING AND SEALING EQUIPMENT 85
5.5 PRICING ANALYSIS 86
TABLE 5 AVERAGE SELLING PRICE (USD): PRIMARY PACKAGING EQUIPMENT 86
TABLE 6 AVERAGE SELLING PRICE (USD): SECONDARY PACKAGING EQUIPMENT 87
TABLE 7 AVERAGE SELLING PRICE (USD): LABELING AND SERIALIZATION EQUIPMENT 87
5.6 SUPPLY CHAIN ANALYSIS 87
FIGURE 33 SUPPLY CHAIN ANALYSIS 88
5.7 VALUE CHAIN ANALYSIS 88
FIGURE 34 VALUE CHAIN OF PHARMACEUTICAL PACKAGING EQUIPMENT MARKET 89
5.8 ECOSYSTEM MARKET MAP 89
FIGURE 35 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET:
ECOSYSTEM MARKET MAP 89
5.9 PORTER’S FIVE FORCES ANALYSIS 90
TABLE 8 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET: PORTER’S FIVE FORCES ANALYSIS 90
5.10 REGULATORY ANALYSIS 92
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
TABLE 9 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
TABLE 10 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 92
TABLE 11 ASIA-PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 93
TABLE 12 REST OF WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93
5.10.2 NORTH AMERICA 94
5.10.2.1 US 94
5.10.2.2 CANADA 94
5.10.3 EUROPE 95
5.10.4 ASIA PACIFIC 95
5.10.4.1 Japan 95
5.10.4.2 China 95
5.10.4.3 India 95
5.10.5 BRAZIL 96
FIGURE 36 BRAZIL: REGULATORY PROCESS FOR PHARMACEUTICAL PACKAGING EQUIPMENT 96
5.11 KEY CONFERENCES & EVENTS IN 2022-2023 97
TABLE 13 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET: DETAILED LIST OF CONFERENCES & EVENTS 97
5.12 YC–YCC TRENDS/DISRUPTION IMPACTING CUSTOMER BUSINESS 98
FIGURE 37 YC–YCC SHIFT IN PHARMACEUTICAL PACKAGING EQUIPMENT MARKET 98
5.13 PATENT ANALYSIS 98
5.13.1 PATENT PUBLICATION TRENDS FOR PHARMACEUTICAL PACKAGING EQUIPMENT 98
FIGURE 38 GLOBAL PATENT PUBLICATION TRENDS IN PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, 2015–2021 99
5.13.2 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN PHARMACEUTICAL PACKAGING EQUIPMENT MARKET 99
FIGURE 39 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR PHARMACEUTICAL PACKAGING EQUIPMENT PATENTS,
2015–2021 99
5.14 TRADE ANALYSIS 100
TABLE 14 PHARMACEUTICAL PACKAGING EQUIPMENT EXPORT AND IMPORT DATA,
BY COUNTRY 100
5.15 CASE STUDY ANALYSIS 101
FIGURE 40 CASE STUDY: SECURITY PACKAGING UPGRADES FOR PHARMACEUTICAL 101
5.15.1 CASE STUDY: QUALITATIVE INSIGHT BASED ON SPEED OF THE MACHINE 102
5.15.1.1 Sachet packaging equipment: 102
5.15.1.2 Blister packaging equipment: 102
5.15.1.3 Cartoning equipment: 104
5.16 IMPACT OF COVID-19 ON PHARMACEUTICAL PACKAGING EQUIPMENT MARKET 107
6 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT 109
6.1 INTRODUCTION 110
TABLE 15 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 110
6.2 PRIMARY PACKAGING EQUIPMENT 110
TABLE 16 PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 111
TABLE 17 PRIMARY PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 112
6.2.1 ASEPTIC FILLING AND SEALING EQUIPMENT 112
6.2.1.1 Technological advancements and automation to drive segment growth 112
TABLE 18 EXAMPLES OF ASEPTIC FILLING AND SEALING EQUIPMENT 113
TABLE 19 ASEPTIC FILLING AND SEALING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 116
6.2.2 BOTTLE FILLING AND CAPPING EQUIPMENT 116
6.2.2.1 Higher adoption of plastic bottles in pharmaceutical packaging to support segment growth 116
TABLE 20 EXAMPLES OF BOTTLE FILLING AND CAPPING EQUIPMENT 117
TABLE 21 BOTTLE FILLING AND CAPPING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 118
6.2.3 BLISTER PACKAGING EQUIPMENT 118
6.2.3.1 Adaptability of blister packs to impact blister packaging equipment demand 118
TABLE 22 EXAMPLES OF BLISTER PACKAGING EQUIPMENT 119
TABLE 23 BLISTER PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 121
6.2.4 SOFT-TUBE FILLING AND SEALING EQUIPMENT 122
6.2.4.1 Increasing demand for soft-tube-based drug formulations and OTC pain relief ointments and creams to aid market growth 122
TABLE 24 EXAMPLES OF SOFT-TUBE FILLING AND SEALING EQUIPMENT 122
TABLE 25 SOFT-TUBE FILLING AND SEALING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 123
6.2.5 SACHET PACKAGING EQUIPMENT 124
6.2.5.1 Increasing applications of sachets and pouches in unit dose packaging to drive segment growth 124
TABLE 26 EXAMPLES OF SACHET PACKAGING EQUIPMENT 124
TABLE 27 SACHET PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 125
6.2.6 STRIP PACKAGING EQUIPMENT 125
6.2.6.1 User-friendly packaging of strips to drive segment growth 125
TABLE 28 EXAMPLES OF STRIP PACKAGING EQUIPMENT 126
TABLE 29 STRIP PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 127
6.2.7 COUNTING EQUIPMENT 127
6.2.7.1 Initiatives to develop remote tablet counting machines to improve accuracy and efficiency in medical dispensing 127
TABLE 30 EXAMPLES OF COUNTING EQUIPMENT 128
TABLE 31 COUNTING EQUIPMENT MARKET, BY COUNTRY, 2020–2027(USD MILLION) 129
6.2.8 OTHER PRIMARY PACKAGING EQUIPMENT 129
TABLE 32 OTHER PRIMARY PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027(USD MILLION) 130
6.3 SECONDARY PACKAGING EQUIPMENT 130
TABLE 33 SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 131
TABLE 34 SECONDARY PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 132
6.3.1 CARTONING EQUIPMENT 132
6.3.1.1 Safe and gentle packaging achieved with cartoning equipment usage to drive segment growth 132
TABLE 35 EXAMPLES OF CARTONING EQUIPMENT 133
TABLE 36 CARTONING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 135
6.3.2 CASE PACKING EQUIPMENT 135
6.3.2.1 Increasing demand for flexible packaging to support market growth 135
TABLE 37 EXAMPLES OF CASE PACKING EQUIPMENT 136
TABLE 38 CASE PACKING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 137
6.3.3 WRAPPING EQUIPMENT 137
6.3.3.1 Wrapping machines offer customization to increase productivity 137
TABLE 39 EXAMPLES OF WRAPPING EQUIPMENT 138
TABLE 40 WRAPPING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 139
6.3.4 TRAY PACKING EQUIPMENT 139
6.3.4.1 Technological advances to support segment growth 139
TABLE 41 EXAMPLES OF TRAY PACKING EQUIPMENT 140
TABLE 42 TRAY PACKING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 140
6.3.5 PALLETIZING AND DEPALLETIZING EQUIPMENT 141
6.3.5.1 Recent developments and automation in palletizing and depalletizing equipment to drive market growth 141
TABLE 43 EXAMPLES OF PALLETIZING AND DEPALLETIZING EQUIPMENT 141
TABLE 44 PALLETIZING AND DEPALLETIZING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 142
6.4 LABELING AND SERIALIZATION EQUIPMENT 142
TABLE 45 LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 143
TABLE 46 LABELING AND SERIALIZATION EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 144
6.4.1 BOTTLE AND AMPOULE LABELING AND SERIALIZATION EQUIPMENT 144
6.4.1.1 Increasing awareness about anti-counterfeit technologies to drive market growth 144
TABLE 47 EXAMPLES OF BOTTLE AND AMPOULE LABELING AND SERIALIZATION EQUIPMENT 145
TABLE 48 BOTTLE AND AMPOULE LABELING AND SERIALIZATION EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 146
6.4.2 CARTON LABELING AND SERIALIZATION EQUIPMENT 146
6.4.2.1 Increasing demand for pharmaceutical products labeling and serialization to drive market growth 146
TABLE 49 EXAMPLES OF CARTON LABELING AND SERIALIZATION EQUIPMENT 147
TABLE 50 CARTON LABELING AND SERIALIZATION EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 147
6.4.3 DATA MATRIX LABELING AND SERIALIZATION EQUIPMENT 148
6.4.3.1 Speed and ease of use to propel segment growth 148
TABLE 51 EXAMPLES OF DATA MATRIX LABELING AND SERIALIZATION EQUIPMENT 148
TABLE 52 DATA MATRIX LABELING AND SERIALIZATION EQUIPMENT MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 149
7 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE 150
7.1 INTRODUCTION 151
TABLE 53 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 151
7.2 LIQUID PACKAGING EQUIPMENT 151
TABLE 54 LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 152
TABLE 55 LIQUID PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 152
7.2.1 ASEPTIC LIQUIDS 153
7.2.1.1 Automation of packaging lines and increasing use of robotics to propel aseptic liquid packaging 153
TABLE 56 EXAMPLES OF ASEPTIC LIQUID PACKAGING EQUIPMENT 154
TABLE 57 ASEPTIC LIQUID PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 157
7.2.2 SYRUPS 158
7.2.2.1 Bottle filling and capping machines to reduce syrup spillage risk 158
TABLE 58 EXAMPLES OF SYRUP PACKAGING EQUIPMENT 158
TABLE 59 SYRUP PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 159
7.2.3 EYE/EAR DROPS 159
7.2.3.1 Technological advancements to increase demand for automated form-fill-seal equipment used for eye/ear drops packaging 159
TABLE 60 EXAMPLES OF EYE/EAR DROP PACKAGING EQUIPMENT 160
TABLE 61 EYE/EAR DROP PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 160
7.2.4 AEROSOLS 161
7.2.4.1 Integration of filling and sealing processes to gain importance in aerosol packaging 161
TABLE 62 EXAMPLES OF AEROSOL PACKAGING EQUIPMENT 161
TABLE 63 AEROSOL PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 162
7.2.5 OTHER LIQUID PACKAGING EQUIPMENT 162
TABLE 64 OTHER LIQUID PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 163
7.3 SOLID PACKAGING EQUIPMENT 163
TABLE 65 SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 164
TABLE 66 SOLID PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 164
7.3.1 TABLETS 165
7.3.1.1 Growing demand for packaging equipment capable of handling smaller batch sizes with higher levels of accuracy and precision to drive segment growth 165
TABLE 67 EXAMPLES OF TABLET PACKAGING EQUIPMENT 165
TABLE 68 TABLET PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 168
7.3.2 CAPSULES 168
7.3.2.1 Capsule-counting machines to integrate with filling and inspection systems 168
TABLE 69 EXAMPLES OF CAPSULE PACKAGING EQUIPMENT 169
TABLE 70 CAPSULE PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 170
7.3.3 POWDERS 170
7.3.3.1 High demand for robotic packaging equipment for powder packaging to proper segment growth 170
TABLE 71 EXAMPLES OF POWDER PACKAGING EQUIPMENT 171
TABLE 72 POWDER PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 172
7.3.4 GRANULES 172
7.3.4.1 Sachets to become most preferred packaging forms for granules 172
TABLE 73 EXAMPLES OF GRANULE PACKAGING EQUIPMENT 173
TABLE 74 GRANULE PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 173
7.3.5 OTHER SOLID PACKAGING EQUIPMENT 174
TABLE 75 OTHER SOLID PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 174
7.4 SEMI-SOLID PACKAGING EQUIPMENT 175
TABLE 76 SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 175
TABLE 77 SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 176
7.4.1 OINTMENTS 176
7.4.1.1 Wide usage to drive pharmaceutical packaging equipment demand 176
TABLE 78 EXAMPLES OF OINTMENT PACKAGING EQUIPMENT 177
TABLE 79 OINTMENT PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 178
7.4.2 CREAMS 178
7.4.2.1 Filling, capping, and sealing machines to package creams 178
TABLE 80 CREAM PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 179
7.4.3 SUPPOSITORIES 179
7.4.3.1 Drying drug pipelines and growing costs to limit segment growth 179
TABLE 81 SUPPOSITORY PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 180
7.4.4 OTHER SEMI-SOLID PACKAGING EQUIPMENT 180
TABLE 82 OTHER SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 181
7.5 OTHER PRODUCT PACKAGING EQUIPMENT 181
TABLE 83 OTHER PRODUCT PACKAGING EQUIPMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 182
8 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY REGION 183
8.1 INTRODUCTION 184
FIGURE 41 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 184
TABLE 84 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY REGION,
2020–2027 (USD MILLION) 185
8.2 EUROPE 185
FIGURE 42 EUROPE: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET SNAPSHOT 186
TABLE 85 EUROPE: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 187
TABLE 86 EUROPE: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY PRODUCT, 2020–2027 (USD MILLION) 187
TABLE 87 EUROPE: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 188
TABLE 88 EUROPE: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 188
TABLE 89 EUROPE: LABELING AND SERIALIZATION EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 189
TABLE 90 EUROPE: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 189
TABLE 91 EUROPE: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 190
TABLE 92 EUROPE: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 190
TABLE 93 EUROPE: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 191
8.2.1 GERMANY 191
8.2.1.1 Germany to witness highest growth rate in European market 191
TABLE 94 GERMANY: KEY MACROINDICATORS 192
TABLE 95 GERMANY: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY PRODUCT, 2020–2027 (USD MILLION) 192
TABLE 96 GERMANY: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 193
TABLE 97 GERMANY: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 193
TABLE 98 GERMANY: LABELING AND SERIALIZATION EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 194
TABLE 99 GERMANY: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 194
TABLE 100 GERMANY: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 195
TABLE 101 GERMANY: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 195
TABLE 102 GERMANY: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 196
8.2.2 ITALY 196
8.2.2.1 Growing consumption of OTC and generic drugs to drive market growth 196
TABLE 103 ITALY: KEY MACROINDICATORS 197
TABLE 104 ITALY: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 197
TABLE 105 ITALY: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 198
TABLE 106 ITALY: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 198
TABLE 107 ITALY: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 199
TABLE 108 ITALY: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 199
TABLE 109 ITALY: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 200
TABLE 110 ITALY: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 200
TABLE 111 ITALY: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 201
8.2.3 UK 201
8.2.3.1 Growth in generics market alongside rising demand for prescription and OTC drugs to drive market growth 201
TABLE 112 UK: KEY MACROINDICATORS 201
TABLE 113 UK: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 202
TABLE 114 UK: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 202
TABLE 115 UK: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 203
TABLE 116 UK: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 203
TABLE 117 UK: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 204
TABLE 118 UK: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 204
TABLE 119 UK: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 205
TABLE 120 UK: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 205
8.2.4 FRANCE 206
8.2.4.1 Presence of leading pharmaceutical companies to drive market growth 206
TABLE 121 FRANCE: KEY MACROINDICATORS 206
TABLE 122 FRANCE: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 206
TABLE 123 FRANCE: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 207
TABLE 124 FRANCE: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 207
TABLE 125 FRANCE: LABELING AND SERIALIZATION EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 208
TABLE 126 FRANCE: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 208
TABLE 127 FRANCE: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 209
TABLE 128 FRANCE: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 209
TABLE 129 FRANCE: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 210
8.2.5 SPAIN 210
8.2.5.1 Rising geriatric population and growing generics market to propel market growth 210
TABLE 130 SPAIN: KEY MACROINDICATORS 211
TABLE 131 SPAIN: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY PRODUCT, 2020–2027 (USD MILLION) 211
TABLE 132 SPAIN: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 212
TABLE 133 SPAIN: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 212
TABLE 134 SPAIN: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 213
TABLE 135 SPAIN: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 213
TABLE 136 SPAIN: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 214
TABLE 137 SPAIN: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 214
TABLE 138 SPAIN: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 215
8.2.6 SWITZERLAND 215
8.2.6.1 Growing generics market to drive market growth 215
TABLE 139 SWITZERLAND: KEY MACROINDICATORS 216
TABLE 140 SWITZERLAND: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY PRODUCT, 2020–2027 (USD MILLION) 216
TABLE 141 SWITZERLAND: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 217
TABLE 142 SWITZERLAND: SECONDARY PACKAGING EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 217
TABLE 143 SWITZERLAND: LABELING AND SERIALIZATION EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 218
TABLE 144 SWITZERLAND: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 218
TABLE 145 SWITZERLAND: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 219
TABLE 146 SWITZERLAND: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 219
TABLE 147 SWITZERLAND: SEMI-SOLID PACKAGING EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 220
8.2.7 REST OF EUROPE 220
TABLE 148 ROE: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 221
TABLE 149 ROE: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 221
TABLE 150 ROE: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 222
TABLE 151 ROE: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 222
TABLE 152 ROE: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 223
TABLE 153 ROE: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 223
TABLE 154 ROE: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 224
TABLE 155 ROE: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 224
8.3 ASIA PACIFIC 225
FIGURE 43 ASIA PACIFIC: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET SNAPSHOT 226
TABLE 156 APAC: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 227
TABLE 157 APAC: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY PRODUCT, 2020–2027 (USD MILLION) 227
TABLE 158 APAC: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 228
TABLE 159 APAC: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 228
TABLE 160 APAC: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 229
TABLE 161 APAC: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 229
TABLE 162 APAC: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 230
TABLE 163 APAC: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 230
TABLE 164 APAC: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 231
8.3.1 CHINA 231
8.3.1.1 Favorable government initiatives to propel market growth 231
TABLE 165 CHINA: KEY MACROINDICATORS 232
TABLE 166 CHINA: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 232
TABLE 167 CHINA: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 233
TABLE 168 CHINA: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 233
TABLE 169 CHINA: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 234
TABLE 170 CHINA: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 234
TABLE 171 CHINA: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 235
TABLE 172 CHINA: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 235
TABLE 173 CHINA: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 236
8.3.2 JAPAN 236
8.3.2.1 Rising geriatric population and growth in generics market to drive market growth 236
TABLE 174 JAPAN: KEY MACROINDICATORS 237
TABLE 175 JAPAN: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 237
TABLE 176 JAPAN: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 238
TABLE 177 JAPAN: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 238
TABLE 178 JAPAN: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 239
TABLE 179 JAPAN: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 239
TABLE 180 JAPAN: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 240
TABLE 181 JAPAN: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 240
TABLE 182 JAPAN: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 241
8.3.3 INDIA 241
8.3.3.1 Low manufacturing cost and skilled workforce to attract outsourcing and investments 241
TABLE 183 INDIA: KEY MACROINDICATORS 242
TABLE 184 INDIA: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY PRODUCT, 2020–2027 (USD MILLION) 242
TABLE 185 INDIA: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 243
TABLE 186 INDIA: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 243
TABLE 187 INDIA: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 244
TABLE 188 INDIA: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 244
TABLE 189 INDIA: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 245
TABLE 190 INDIA: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 245
TABLE 191 INDIA: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 246
8.3.4 SOUTH KOREA 246
8.3.4.1 Rising healthcare spending and increasing government initiatives to propel clinical trials 246
TABLE 192 COUNTRIES BUYING THE MOST KOREAN DRUGS 247
TABLE 193 SOUTH KOREA: KEY MACROINDICATORS 247
TABLE 194 SOUTH KOREA: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY PRODUCT, 2020–2027 (USD MILLION) 247
TABLE 195 SOUTH KOREA: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 248
TABLE 196 SOUTH KOREA: SECONDARY PACKAGING EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 248
TABLE 197 SOUTH KOREA: LABELING AND SERIALIZATION EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 249
TABLE 198 SOUTH KOREA: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 249
TABLE 199 SOUTH KOREA: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 250
TABLE 200 SOUTH KOREA: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 250
TABLE 201 SOUTH KOREA: SEMI-SOLID PACKAGING EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 251
8.3.5 REST OF APAC 251
TABLE 202 ROAPAC: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY PRODUCT, 2020–2027 (USD MILLION) 252
TABLE 203 ROAPAC: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 252
TABLE 204 ROAPAC: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 253
TABLE 205 ROAPAC: LABELING AND SERIALIZATION EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 253
TABLE 206 ROAPAC: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 254
TABLE 207 ROAPAC: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 254
TABLE 208 ROAPAC: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 255
TABLE 209 ROAPAC: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 255 1 INTRODUCTION 39 1.1 OBJECTIVES OF THE STUDY 39 1.2 MARKET DEFINITION 40 1.2.1 INCLUSIONS AND EXCLUSIONS 40 1.3 MARKET SCOPE 41 1.3.1 MARKETS COVERED 41 FIGURE 1 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET SEGMENTATION 41 1.3.2 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET: BY REGION 42 1.4 YEARS CONSIDERED FOR THE STUDY 42 1.5 CURRENCY 43 TABLE 1 STANDARD CURRENCY CONVERSION RATES 43 1.6 LIMITATIONS 43 1.7 STAKEHOLDERS 43 1.8 SUMMARY OF CHANGES 44 2 RESEARCH METHODOLOGY 45 2.1 RESEARCH DATA 45 FIGURE 2 RESEARCH DESIGN 45 2.1.1 SECONDARY DATA 46 2.1.1.1 Key data from secondary sources 47 2.1.2 PRIMARY DATA 48 FIGURE 3 PRIMARY SOURCES 48 2.1.2.1 Key data from primary sources 49 2.1.2.2 Key industry insights 50 FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS 50 FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 51 FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 51 2.2 MARKET SIZE ESTIMATION 52 FIGURE 7 SUPPLY SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 52 FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION: SYNTEGON TECHNOLOGY GMBH 53 FIGURE 9 SUPPLY SIDE MARKET SIZE ESTIMATION: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET (2020) 54 FIGURE 10 APPROACH 3: BASED ON SOURCE, BY REGION (2022) 55 FIGURE 11 TOP-DOWN APPROACH 55 FIGURE 12 CAGR PROJECTIONS FROM DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES ANALYSIS (2022–2027) 57 FIGURE 13 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS 57 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 58 FIGURE 14 DATA TRIANGULATION METHODOLOGY 59 2.4 MARKET SHARE ESTIMATION 60 2.5 ASSUMPTIONS FOR THE STUDY 60 2.6 LIMITATIONS 60 2.6.1 METHODOLOGY-RELATED LIMITATIONS 61 2.7 RISK ASSESSMENT 61 TABLE 2 RISK ASSESSMENT: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET 61 2.8 ASSESSMENT OF COVID-19 IMPACT ON ECONOMIC SCENARIO 61 3 EXECUTIVE SUMMARY 63 FIGURE 15 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION) 63 FIGURE 16 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 64 FIGURE 17 GEOGRAPHICAL SNAPSHOT OF PHARMACEUTICAL PACKAGING EQUIPMENT MARKET 65 4 PREMIUM INSIGHTS 66 4.1 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET OVERVIEW 66 FIGURE 18 RISING NEED FOR FLEXIBLE AND INTEGRATED PACKAGING EQUIPMENT TO DRIVE MARKET GROWTH 66 4.2 ASIA PACIFIC: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT AND COUNTRY (2021) 67 FIGURE 19 PRIMARY PACKAGING EQUIPMENT SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF APAC MARKET IN 2021 67 4.3 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 68 FIGURE 20 CHINA TO REGISTER THE HIGHEST GROWTH DURING FORECAST PERIOD 68 4.4 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, REGIONAL MIX, 2022−2027 68 FIGURE 21 EUROPE TO DOMINATE PHARMACEUTICAL PACKAGING EQUIPMENT MARKET 68 4.5 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET: DEVELOPING VS. DEVELOPED MARKETS 69 FIGURE 22 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD 69 5 MARKET OVERVIEW 70 5.1 INTRODUCTION 70 5.2 MARKET DYNAMICS 70 FIGURE 23 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 70 5.2.1 DRIVERS 71 5.2.1.1 High growth in generics & biopharmaceuticals markets 71 FIGURE 24 SALES OF GENERIC DRUGS GLOBALLY, 2006–2020 (USD BILLION) 71 FIGURE 25 GLOBAL PHARMACEUTICALS MARKET (USD BILLION) 71 TABLE 3 LIST OF OFF-PATENT DRUGS, 2015−2029 72 5.2.1.2 Growing need for flexible and integrated packaging equipment 73 5.2.1.3 Increase in offshore pharmaceutical manufacturing 73 FIGURE 26 PHARMACEUTICAL IMPORTS AND EXPORTS, BY COUNTRY, 2020 (USD BILLION) 74 5.2.1.4 Growing contract manufacturing of pharmaceutical products 74 5.2.1.5 Introduction of regulatory standards on packaging and stringent norms against counterfeit products 74 TABLE 4 KEY REGULATIONS & STANDARDS GOVERNING PHARMACEUTICAL PACKAGING EQUIPMENT 75 5.2.1.6 Innovation in pharmaceutical packaging and delivery system 75 5.2.1.7 Growth in OTC drug sales and regulations to reduce OTC counterfeit 76 FIGURE 27 GLOBAL OTC PHARMACEUTICALS MARKET SIZE, 2020 (USD BILLION) 76 5.2.2 RESTRAINTS 76 5.2.2.1 Growing preference for refurbished equipment 76 5.2.3 OPPORTUNITIES 77 5.2.3.1 Growth of pharmaceutical manufacturing in emerging economies 77 5.2.3.2 Rising demand for automated packaging 77 5.2.3.3 Change in medication systems to self-medication and self-care 78 5.2.3.4 Increasing pharmaceutical R&D investments 78 FIGURE 28 PHARMACEUTICAL & BIOPHARMACEUTICAL R&D EXPENDITURE, 2017–2024 79 FIGURE 29 NUMBER OF REGISTERED STUDIES, 2001-2022 (AS OF FEBRUARY 22, 2022) 79 FIGURE 30 NUMBER OF PIPELINE DRUGS, BY COMPANY, 2019 80 5.2.4 CHALLENGES 80 5.2.4.1 Growth in personalized and precision medicine supply chain 80 5.2.4.2 Uncertainties in regulations and standards of pharmaceutical packaging process 81 5.3 TECHNOLOGICAL ROADMAP 82 FIGURE 31 PHARMACEUTICAL PACKAGING EQUIPMENT: TECHNOLOGICAL ROADMAP 82 5.4 INDUSTRY TRENDS 83 FIGURE 32 MAJOR TRENDS IN PHARMACEUTICAL PACKAGING EQUIPMENT MARKET 83 5.4.1 DEVELOPMENT OF PRODUCTION LINES FOR SMALL BATCH SIZES AND RESEARCH PURPOSES 83 5.4.2 AUTOMATION AND INTEGRATION OF PACKAGING EQUIPMENT 84 5.4.3 GROWING FOCUS ON LABELING AND SERIALIZATION FOR ANTI-COUNTERFEITING OF DRUGS 85 5.4.4 GROWING DEMAND FOR ASEPTIC FILLING AND SEALING EQUIPMENT 85 5.5 PRICING ANALYSIS 86 TABLE 5 AVERAGE SELLING PRICE (USD): PRIMARY PACKAGING EQUIPMENT 86 TABLE 6 AVERAGE SELLING PRICE (USD): SECONDARY PACKAGING EQUIPMENT 87 TABLE 7 AVERAGE SELLING PRICE (USD): LABELING AND SERIALIZATION EQUIPMENT 87 5.6 SUPPLY CHAIN ANALYSIS 87 FIGURE 33 SUPPLY CHAIN ANALYSIS 88 5.7 VALUE CHAIN ANALYSIS 88 FIGURE 34 VALUE CHAIN OF PHARMACEUTICAL PACKAGING EQUIPMENT MARKET 89 5.8 ECOSYSTEM MARKET MAP 89 FIGURE 35 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET: ECOSYSTEM MARKET MAP 89 5.9 PORTER’S FIVE FORCES ANALYSIS 90 TABLE 8 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET: PORTER’S FIVE FORCES ANALYSIS 90 5.10 REGULATORY ANALYSIS 92 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92 TABLE 9 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92 TABLE 10 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92 TABLE 11 ASIA-PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93 TABLE 12 REST OF WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93 5.10.2 NORTH AMERICA 94 5.10.2.1 US 94 5.10.2.2 CANADA 94 5.10.3 EUROPE 95 5.10.4 ASIA PACIFIC 95 5.10.4.1 Japan 95 5.10.4.2 China 95 5.10.4.3 India 95 5.10.5 BRAZIL 96 FIGURE 36 BRAZIL: REGULATORY PROCESS FOR PHARMACEUTICAL PACKAGING EQUIPMENT 96 5.11 KEY CONFERENCES & EVENTS IN 2022-2023 97 TABLE 13 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET: DETAILED LIST OF CONFERENCES & EVENTS 97 5.12 YC–YCC TRENDS/DISRUPTION IMPACTING CUSTOMER BUSINESS 98 FIGURE 37 YC–YCC SHIFT IN PHARMACEUTICAL PACKAGING EQUIPMENT MARKET 98 5.13 PATENT ANALYSIS 98 5.13.1 PATENT PUBLICATION TRENDS FOR PHARMACEUTICAL PACKAGING EQUIPMENT 98 FIGURE 38 GLOBAL PATENT PUBLICATION TRENDS IN PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, 2015–2021 99 5.13.2 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN PHARMACEUTICAL PACKAGING EQUIPMENT MARKET 99 FIGURE 39 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR PHARMACEUTICAL PACKAGING EQUIPMENT PATENTS, 2015–2021 99 5.14 TRADE ANALYSIS 100 TABLE 14 PHARMACEUTICAL PACKAGING EQUIPMENT EXPORT AND IMPORT DATA, BY COUNTRY 100 5.15 CASE STUDY ANALYSIS 101 FIGURE 40 CASE STUDY: SECURITY PACKAGING UPGRADES FOR PHARMACEUTICAL 101 5.15.1 CASE STUDY: QUALITATIVE INSIGHT BASED ON SPEED OF THE MACHINE 102 5.15.1.1 Sachet packaging equipment: 102 5.15.1.2 Blister packaging equipment: 102 5.15.1.3 Cartoning equipment: 104 5.16 IMPACT OF COVID-19 ON PHARMACEUTICAL PACKAGING EQUIPMENT MARKET 107 6 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT 109 6.1 INTRODUCTION 110 TABLE 15 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 110 6.2 PRIMARY PACKAGING EQUIPMENT 110 TABLE 16 PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 111 TABLE 17 PRIMARY PACKAGING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 112 6.2.1 ASEPTIC FILLING AND SEALING EQUIPMENT 112 6.2.1.1 Technological advancements and automation to drive segment growth 112 TABLE 18 EXAMPLES OF ASEPTIC FILLING AND SEALING EQUIPMENT 113 TABLE 19 ASEPTIC FILLING AND SEALING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 116 6.2.2 BOTTLE FILLING AND CAPPING EQUIPMENT 116 6.2.2.1 Higher adoption of plastic bottles in pharmaceutical packaging to support segment growth 116 TABLE 20 EXAMPLES OF BOTTLE FILLING AND CAPPING EQUIPMENT 117 TABLE 21 BOTTLE FILLING AND CAPPING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 118 6.2.3 BLISTER PACKAGING EQUIPMENT 118 6.2.3.1 Adaptability of blister packs to impact blister packaging equipment demand 118 TABLE 22 EXAMPLES OF BLISTER PACKAGING EQUIPMENT 119 TABLE 23 BLISTER PACKAGING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 121 6.2.4 SOFT-TUBE FILLING AND SEALING EQUIPMENT 122 6.2.4.1 Increasing demand for soft-tube-based drug formulations and OTC pain relief ointments and creams to aid market growth 122 TABLE 24 EXAMPLES OF SOFT-TUBE FILLING AND SEALING EQUIPMENT 122 TABLE 25 SOFT-TUBE FILLING AND SEALING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 123 6.2.5 SACHET PACKAGING EQUIPMENT 124 6.2.5.1 Increasing applications of sachets and pouches in unit dose packaging to drive segment growth 124 TABLE 26 EXAMPLES OF SACHET PACKAGING EQUIPMENT 124 TABLE 27 SACHET PACKAGING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 125 6.2.6 STRIP PACKAGING EQUIPMENT 125 6.2.6.1 User-friendly packaging of strips to drive segment growth 125 TABLE 28 EXAMPLES OF STRIP PACKAGING EQUIPMENT 126 TABLE 29 STRIP PACKAGING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 127 6.2.7 COUNTING EQUIPMENT 127 6.2.7.1 Initiatives to develop remote tablet counting machines to improve accuracy and efficiency in medical dispensing 127 TABLE 30 EXAMPLES OF COUNTING EQUIPMENT 128 TABLE 31 COUNTING EQUIPMENT MARKET, BY COUNTRY, 2020–2027(USD MILLION) 129 6.2.8 OTHER PRIMARY PACKAGING EQUIPMENT 129 TABLE 32 OTHER PRIMARY PACKAGING EQUIPMENT MARKET, BY COUNTRY, 2020–2027(USD MILLION) 130 6.3 SECONDARY PACKAGING EQUIPMENT 130 TABLE 33 SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 131 TABLE 34 SECONDARY PACKAGING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 132 6.3.1 CARTONING EQUIPMENT 132 6.3.1.1 Safe and gentle packaging achieved with cartoning equipment usage to drive segment growth 132 TABLE 35 EXAMPLES OF CARTONING EQUIPMENT 133 TABLE 36 CARTONING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 135 6.3.2 CASE PACKING EQUIPMENT 135 6.3.2.1 Increasing demand for flexible packaging to support market growth 135 TABLE 37 EXAMPLES OF CASE PACKING EQUIPMENT 136 TABLE 38 CASE PACKING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 137 6.3.3 WRAPPING EQUIPMENT 137 6.3.3.1 Wrapping machines offer customization to increase productivity 137 TABLE 39 EXAMPLES OF WRAPPING EQUIPMENT 138 TABLE 40 WRAPPING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 139 6.3.4 TRAY PACKING EQUIPMENT 139 6.3.4.1 Technological advances to support segment growth 139 TABLE 41 EXAMPLES OF TRAY PACKING EQUIPMENT 140 TABLE 42 TRAY PACKING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 140 6.3.5 PALLETIZING AND DEPALLETIZING EQUIPMENT 141 6.3.5.1 Recent developments and automation in palletizing and depalletizing equipment to drive market growth 141 TABLE 43 EXAMPLES OF PALLETIZING AND DEPALLETIZING EQUIPMENT 141 TABLE 44 PALLETIZING AND DEPALLETIZING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 142 6.4 LABELING AND SERIALIZATION EQUIPMENT 142 TABLE 45 LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 143 TABLE 46 LABELING AND SERIALIZATION EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 144 6.4.1 BOTTLE AND AMPOULE LABELING AND SERIALIZATION EQUIPMENT 144 6.4.1.1 Increasing awareness about anti-counterfeit technologies to drive market growth 144 TABLE 47 EXAMPLES OF BOTTLE AND AMPOULE LABELING AND SERIALIZATION EQUIPMENT 145 TABLE 48 BOTTLE AND AMPOULE LABELING AND SERIALIZATION EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 146 6.4.2 CARTON LABELING AND SERIALIZATION EQUIPMENT 146 6.4.2.1 Increasing demand for pharmaceutical products labeling and serialization to drive market growth 146 TABLE 49 EXAMPLES OF CARTON LABELING AND SERIALIZATION EQUIPMENT 147 TABLE 50 CARTON LABELING AND SERIALIZATION EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 147 6.4.3 DATA MATRIX LABELING AND SERIALIZATION EQUIPMENT 148 6.4.3.1 Speed and ease of use to propel segment growth 148 TABLE 51 EXAMPLES OF DATA MATRIX LABELING AND SERIALIZATION EQUIPMENT 148 TABLE 52 DATA MATRIX LABELING AND SERIALIZATION EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 149 7 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE 150 7.1 INTRODUCTION 151 TABLE 53 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 151 7.2 LIQUID PACKAGING EQUIPMENT 151 TABLE 54 LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 152 TABLE 55 LIQUID PACKAGING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 152 7.2.1 ASEPTIC LIQUIDS 153 7.2.1.1 Automation of packaging lines and increasing use of robotics to propel aseptic liquid packaging 153 TABLE 56 EXAMPLES OF ASEPTIC LIQUID PACKAGING EQUIPMENT 154 TABLE 57 ASEPTIC LIQUID PACKAGING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 157 7.2.2 SYRUPS 158 7.2.2.1 Bottle filling and capping machines to reduce syrup spillage risk 158 TABLE 58 EXAMPLES OF SYRUP PACKAGING EQUIPMENT 158 TABLE 59 SYRUP PACKAGING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 159 7.2.3 EYE/EAR DROPS 159 7.2.3.1 Technological advancements to increase demand for automated form-fill-seal equipment used for eye/ear drops packaging 159 TABLE 60 EXAMPLES OF EYE/EAR DROP PACKAGING EQUIPMENT 160 TABLE 61 EYE/EAR DROP PACKAGING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 160 7.2.4 AEROSOLS 161 7.2.4.1 Integration of filling and sealing processes to gain importance in aerosol packaging 161 TABLE 62 EXAMPLES OF AEROSOL PACKAGING EQUIPMENT 161 TABLE 63 AEROSOL PACKAGING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 162 7.2.5 OTHER LIQUID PACKAGING EQUIPMENT 162 TABLE 64 OTHER LIQUID PACKAGING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 163 7.3 SOLID PACKAGING EQUIPMENT 163 TABLE 65 SOLID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 164 TABLE 66 SOLID PACKAGING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 164 7.3.1 TABLETS 165 7.3.1.1 Growing demand for packaging equipment capable of handling smaller batch sizes with higher levels of accuracy and precision to drive segment growth 165 TABLE 67 EXAMPLES OF TABLET PACKAGING EQUIPMENT 165 TABLE 68 TABLET PACKAGING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 168 7.3.2 CAPSULES 168 7.3.2.1 Capsule-counting machines to integrate with filling and inspection systems 168 TABLE 69 EXAMPLES OF CAPSULE PACKAGING EQUIPMENT 169 TABLE 70 CAPSULE PACKAGING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 170 7.3.3 POWDERS 170 7.3.3.1 High demand for robotic packaging equipment for powder packaging to proper segment growth 170 TABLE 71 EXAMPLES OF POWDER PACKAGING EQUIPMENT 171 TABLE 72 POWDER PACKAGING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 172 7.3.4 GRANULES 172 7.3.4.1 Sachets to become most preferred packaging forms for granules 172 TABLE 73 EXAMPLES OF GRANULE PACKAGING EQUIPMENT 173 TABLE 74 GRANULE PACKAGING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 173 7.3.5 OTHER SOLID PACKAGING EQUIPMENT 174 TABLE 75 OTHER SOLID PACKAGING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 174 7.4 SEMI-SOLID PACKAGING EQUIPMENT 175 TABLE 76 SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 175 TABLE 77 SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 176 7.4.1 OINTMENTS 176 7.4.1.1 Wide usage to drive pharmaceutical packaging equipment demand 176 TABLE 78 EXAMPLES OF OINTMENT PACKAGING EQUIPMENT 177 TABLE 79 OINTMENT PACKAGING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 178 7.4.2 CREAMS 178 7.4.2.1 Filling, capping, and sealing machines to package creams 178 TABLE 80 CREAM PACKAGING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 179 7.4.3 SUPPOSITORIES 179 7.4.3.1 Drying drug pipelines and growing costs to limit segment growth 179 TABLE 81 SUPPOSITORY PACKAGING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 180 7.4.4 OTHER SEMI-SOLID PACKAGING EQUIPMENT 180 TABLE 82 OTHER SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 181 7.5 OTHER PRODUCT PACKAGING EQUIPMENT 181 TABLE 83 OTHER PRODUCT PACKAGING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 182 8 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY REGION 183 8.1 INTRODUCTION 184 FIGURE 41 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 184 TABLE 84 PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY REGION, 2020–2027 (USD MILLION) 185 8.2 EUROPE 185 FIGURE 42 EUROPE: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET SNAPSHOT 186 TABLE 85 EUROPE: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 187 TABLE 86 EUROPE: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 187 TABLE 87 EUROPE: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 188 TABLE 88 EUROPE: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 188 TABLE 89 EUROPE: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 189 TABLE 90 EUROPE: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 189 TABLE 91 EUROPE: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 190 TABLE 92 EUROPE: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 190 TABLE 93 EUROPE: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 191 8.2.1 GERMANY 191 8.2.1.1 Germany to witness highest growth rate in European market 191 TABLE 94 GERMANY: KEY MACROINDICATORS 192 TABLE 95 GERMANY: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 192 TABLE 96 GERMANY: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 193 TABLE 97 GERMANY: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 193 TABLE 98 GERMANY: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 194 TABLE 99 GERMANY: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 194 TABLE 100 GERMANY: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 195 TABLE 101 GERMANY: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 195 TABLE 102 GERMANY: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 196 8.2.2 ITALY 196 8.2.2.1 Growing consumption of OTC and generic drugs to drive market growth 196 TABLE 103 ITALY: KEY MACROINDICATORS 197 TABLE 104 ITALY: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 197 TABLE 105 ITALY: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 198 TABLE 106 ITALY: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 198 TABLE 107 ITALY: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 199 TABLE 108 ITALY: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 199 TABLE 109 ITALY: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 200 TABLE 110 ITALY: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 200 TABLE 111 ITALY: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 201 8.2.3 UK 201 8.2.3.1 Growth in generics market alongside rising demand for prescription and OTC drugs to drive market growth 201 TABLE 112 UK: KEY MACROINDICATORS 201 TABLE 113 UK: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 202 TABLE 114 UK: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 202 TABLE 115 UK: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 203 TABLE 116 UK: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 203 TABLE 117 UK: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 204 TABLE 118 UK: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 204 TABLE 119 UK: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 205 TABLE 120 UK: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 205 8.2.4 FRANCE 206 8.2.4.1 Presence of leading pharmaceutical companies to drive market growth 206 TABLE 121 FRANCE: KEY MACROINDICATORS 206 TABLE 122 FRANCE: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 206 TABLE 123 FRANCE: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 207 TABLE 124 FRANCE: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 207 TABLE 125 FRANCE: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 208 TABLE 126 FRANCE: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 208 TABLE 127 FRANCE: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 209 TABLE 128 FRANCE: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 209 TABLE 129 FRANCE: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 210 8.2.5 SPAIN 210 8.2.5.1 Rising geriatric population and growing generics market to propel market growth 210 TABLE 130 SPAIN: KEY MACROINDICATORS 211 TABLE 131 SPAIN: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 211 TABLE 132 SPAIN: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 212 TABLE 133 SPAIN: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 212 TABLE 134 SPAIN: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 213 TABLE 135 SPAIN: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 213 TABLE 136 SPAIN: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 214 TABLE 137 SPAIN: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 214 TABLE 138 SPAIN: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 215 8.2.6 SWITZERLAND 215 8.2.6.1 Growing generics market to drive market growth 215 TABLE 139 SWITZERLAND: KEY MACROINDICATORS 216 TABLE 140 SWITZERLAND: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 216 TABLE 141 SWITZERLAND: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 217 TABLE 142 SWITZERLAND: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 217 TABLE 143 SWITZERLAND: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 218 TABLE 144 SWITZERLAND: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 218 TABLE 145 SWITZERLAND: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 219 TABLE 146 SWITZERLAND: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 219 TABLE 147 SWITZERLAND: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 220 8.2.7 REST OF EUROPE 220 TABLE 148 ROE: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 221 TABLE 149 ROE: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 221 TABLE 150 ROE: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 222 TABLE 151 ROE: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 222 TABLE 152 ROE: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 223 TABLE 153 ROE: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 223 TABLE 154 ROE: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 224 TABLE 155 ROE: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 224 8.3 ASIA PACIFIC 225 FIGURE 43 ASIA PACIFIC: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET SNAPSHOT 226 TABLE 156 APAC: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 227 TABLE 157 APAC: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 227 TABLE 158 APAC: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 228 TABLE 159 APAC: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 228 TABLE 160 APAC: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 229 TABLE 161 APAC: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 229 TABLE 162 APAC: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 230 TABLE 163 APAC: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 230 TABLE 164 APAC: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 231 8.3.1 CHINA 231 8.3.1.1 Favorable government initiatives to propel market growth 231 TABLE 165 CHINA: KEY MACROINDICATORS 232 TABLE 166 CHINA: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 232 TABLE 167 CHINA: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 233 TABLE 168 CHINA: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 233 TABLE 169 CHINA: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 234 TABLE 170 CHINA: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 234 TABLE 171 CHINA: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 235 TABLE 172 CHINA: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 235 TABLE 173 CHINA: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 236 8.3.2 JAPAN 236 8.3.2.1 Rising geriatric population and growth in generics market to drive market growth 236 TABLE 174 JAPAN: KEY MACROINDICATORS 237 TABLE 175 JAPAN: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 237 TABLE 176 JAPAN: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 238 TABLE 177 JAPAN: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 238 TABLE 178 JAPAN: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 239 TABLE 179 JAPAN: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 239 TABLE 180 JAPAN: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 240 TABLE 181 JAPAN: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 240 TABLE 182 JAPAN: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 241 8.3.3 INDIA 241 8.3.3.1 Low manufacturing cost and skilled workforce to attract outsourcing and investments 241 TABLE 183 INDIA: KEY MACROINDICATORS 242 TABLE 184 INDIA: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 242 TABLE 185 INDIA: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 243 TABLE 186 INDIA: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 243 TABLE 187 INDIA: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 244 TABLE 188 INDIA: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 244 TABLE 189 INDIA: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 245 TABLE 190 INDIA: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 245 TABLE 191 INDIA: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 246 8.3.4 SOUTH KOREA 246 8.3.4.1 Rising healthcare spending and increasing government initiatives to propel clinical trials 246 TABLE 192 COUNTRIES BUYING THE MOST KOREAN DRUGS 247 TABLE 193 SOUTH KOREA: KEY MACROINDICATORS 247 TABLE 194 SOUTH KOREA: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 247 TABLE 195 SOUTH KOREA: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 248 TABLE 196 SOUTH KOREA: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 248 TABLE 197 SOUTH KOREA: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 249 TABLE 198 SOUTH KOREA: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 249 TABLE 199 SOUTH KOREA: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 250 TABLE 200 SOUTH KOREA: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 250 TABLE 201 SOUTH KOREA: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 251 8.3.5 REST OF APAC 251 TABLE 202 ROAPAC: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 252 TABLE 203 ROAPAC: PRIMARY PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 252 TABLE 204 ROAPAC: SECONDARY PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 253 TABLE 205 ROAPAC: LABELING AND SERIALIZATION EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 253 TABLE 206 ROAPAC: PHARMACEUTICAL PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 254 TABLE 207 ROAPAC: LIQUID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 254 TABLE 208 ROAPAC: SOLID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 255 TABLE 209 ROAPAC: SEMI-SOLID PACKAGING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 255

Contract Research Organization (CROs) Services Market by Type (Early phase, Clinical, Lab, Consulting), Therapeutic Area (Oncology, Infectious Disease...

Publisher: MarketsandMarkets

# of Pages: 408

Publication Date: March, 2022

Price: $4,950 / User License

1 INTRODUCTION 55
1.1 OBJECTIVES OF THE STUDY 55
1.2 MARKET DEFINITION 56
1.2.1 INCLUSIONS & EXCLUSIONS 56
1.3 MARKET SCOPE 57
FIGURE 1 CRO SERVICES MARKET 57
1.3.1 YEARS CONSIDERED FOR THE STUDY 58
1.4 CURRENCY 58
1.5 LIMITATIONS 58
1.6 STAKEHOLDERS 59
1.7 SUMMARY OF CHANGES 59
2 RESEARCH METHODOLOGY 61
2.1 RESEARCH DATA 61
FIGURE 2 RESEARCH DESIGN 61
2.1.1 SECONDARY DATA 62
2.1.2 PRIMARY DATA 62
FIGURE 3 CRO SERVICES MARKET: BREAKDOWN OF PRIMARIES 63
2.2 MARKET SIZE ESTIMATION 64
FIGURE 4 MARKET SIZE ESTIMATION—BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF CRO SERVICES IN THE MARKET 64
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2021 64
FIGURE 6 AVERAGE MARKET SIZE ESTIMATION, 2021 65
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST 66
FIGURE 7 CRO SERVICES MARKET: CAGR PROJECTIONS, 2022–2027 67
FIGURE 8 CRO SERVICES MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, AND OPPORTUNITIES 67
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 68
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 69
FIGURE 10 DATA TRIANGULATION METHODOLOGY 69
2.5 INSIGHTS FROM PRIMARIES 70
FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS 70
2.6 RESEARCH ASSUMPTIONS 70
2.6.1 COVID-19-SPECIFIC ASSUMPTIONS 71
2.7 RISK ANALYSIS 71
3 EXECUTIVE SUMMARY 72
FIGURE 12 CRO SERVICES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 72
FIGURE 13 CRO SERVICES MARKET, BY THERAPEUTIC AREA,
2022 VS. 2027 (USD MILLION) 73
FIGURE 14 CRO SERVICES MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 74
FIGURE 15 GEOGRAPHICAL SNAPSHOT: CRO SERVICES MARKET 75
4 PREMIUM INSIGHTS 76
4.1 CRO SERVICES MARKET OVERVIEW 76
FIGURE 16 RISING INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET GROWTH 76
4.2 NORTH AMERICA: CRO SERVICES MARKET SHARE, BY SERVICE & COUNTRY (2021) 77
FIGURE 17 CLINICAL RESEARCH SERVICES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN CRO SERVICES MARKET IN 2021 77
4.3 CRO SERVICES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 78
FIGURE 18 CLINICAL RESEARCH SERVICES SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2027 78
4.4 CRO SERVICES MARKET SHARE, BY END USER, 2021 78
FIGURE 19 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2021 78
4.5 CRO SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 79
FIGURE 20 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH IN THE CRO SERVICES MARKET FROM 2022 TO 2027 79
5 MARKET OVERVIEW 80
5.1 INTRODUCTION 80
5.2 MARKET DYNAMICS 80
FIGURE 21 CRO SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 80
TABLE 1 CRO SERVICES MARKET: IMPACT ANALYSIS 81
5.2.1 DRIVERS 81
5.2.1.1 Increasing investment in pharmaceutical R&D 81
FIGURE 22 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–2026 82
FIGURE 23 ACTIVE PHARMACEUTICAL PIPELINE, 2011–2021 83
5.2.1.2 Increasing number of clinical trial 83
FIGURE 24 NUMBER OF CLINICAL TRIALS REGISTERED WORLDWIDE (2000–2021) 83
5.2.1.3 High cost of in-house drug development 84
FIGURE 25 AVERAGE COST TO DEVELOP A PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 2010–2020 (USD BILLION) 84
5.2.1.4 Rising prevalence of orphan and rare diseases 85
5.2.2 OPPORTUNITIES 85
5.2.2.1 Growth in the drugs and biologics market despite the COVID-19 pandemic 85
FIGURE 26 TOTAL NUMBER OF NEW DRUGS (NEW CHEMICAL ENTITIES AND BIOLOGICS) APPROVED BY THE US FDA (2011–2021) 85
TABLE 2 LIST OF BIOLOGICS APPROVED BY THE US FDA (2021) 86
5.2.2.2 Rising demand for specialized testing services among end users 86
5.2.2.3 Need for novel clinical trial designs for complex cell and gene therapies 87
5.2.3 CHALLENGES 87
5.2.3.1 Shortage of skilled professionals for clinical trials 87
5.2.3.2 Requirement for unique analytical testing approaches for innovative formulations 88
5.2.4 MARKET TRENDS 88
5.2.4.1 Growing adoption of artificial intelligence-based tools for drug discovery 88
5.2.4.2 Increased outsourcing to emerging Asian economies 89
5.2.4.3 CRO industry consolidation 90
TABLE 3 LIST OF ACQUISITIONS 90
5.2.4.4 Integrated end-to-end R&D service solutions 91
5.3 RANGES/SCENARIOS 91
FIGURE 27 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE CRO SERVICES MARKET 91
5.4 IMPACT OF COVID-19 OUTBREAK ON THE CRO SERVICES MARKET 92
FIGURE 28 CRO SERVICES MARKET SCENARIO WITH AND WITHOUT COVID-19 IMPACT, 2019–2021 92
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 94
FIGURE 29 REVENUE SHIFT & NEW POCKETS FOR CRO SERVICE PROVIDERS 94
5.6 PRICING ANALYSIS 94
TABLE 4 AVERAGE SELLING PRICE OF CRO SERVICES, BY REGION (2020) 95
5.7 VALUE CHAIN ANALYSIS 95
FIGURE 30 VALUE CHAIN ANALYSIS OF THE CRO SERVICES MARKET: CLINICAL RESEARCH PHASES ADD MAXIMUM VALUE 96
5.8 ECOSYSTEM ANALYSIS 97
FIGURE 31 ECOSYSTEM ANALYSIS: CRO SERVICES MARKET 97
TABLE 5 SUPPLY CHAIN ECOSYSTEM 98
5.9 TECHNOLOGY ANALYSIS 99
5.10 CASE STUDIES 100
5.10.1 COVANCE FSPX DATA ANALYSIS WAS USED TO DETERMINE THE ELIGIBILITY OF PATIENTS ENROLLED FOR ONCOLOGY CLINICAL TRIALS 100
5.10.2 IQVIA PROVIDES END-TO-END CLINICAL SUPPORT TO SPONSOR 100
5.11 KEY CONFERENCES & EVENTS IN 2022–2023 100
TABLE 6 CRO SERVICES MARKET: DETAILED LIST OF CONFERENCES & EVENTS 100
5.12 REGULATORY ANALYSIS 101
5.12.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 101
TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 101
TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 102
TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103
TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103
5.13 PORTER’S FIVE FORCES ANALYSIS 107
TABLE 11 CRO SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 107
5.13.1 THREAT OF NEW ENTRANTS 107
5.13.2 THREAT OF SUBSTITUTES 107
5.13.3 BARGAINING POWER OF BUYERS 108
5.13.4 BARGAINING POWER OF SUPPLIERS 108
5.13.5 DEGREE OF COMPETITION 108
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 109
5.14.1 KEY STAKEHOLDERS IN THE BUYING PROCESS 109
FIGURE 32 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS OF CRO SERVICES 109
5.14.2 BUYING CRITERIA FOR CRO SERVICES 109
FIGURE 33 KEY BUYING CRITERIA FOR END USERS 109
6 CRO SERVICES MARKET, BY TYPE 110
6.1 INTRODUCTION 111
TABLE 12 CRO SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 111
6.2 CLINICAL RESEARCH SERVICES 111
TABLE 13 NUMBER OF REGISTERED AND RECRUITING CLINICAL STUDIES AS OF MARCH 2022, BY LOCATION 112
TABLE 14 EXAMPLES OF CLINICAL RESEARCH SERVICES OFFERED BY MARKET PLAYERS 112
FIGURE 34 DRUGS IN PIPELINE, BY DEVELOPMENT PHASE, 2020 VS. 2021 113
TABLE 15 CLINICAL RESEARCH SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 114
TABLE 16 CLINICAL RESEARCH SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 114
TABLE 17 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 114
TABLE 18 EUROPE: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 115
TABLE 19 ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 115
TABLE 20 LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 115
6.2.1 PHASE III CLINICAL RESEARCH SERVICES 116
6.2.1.1 Rising cost of Phase III trials and high number of patients recruited in these trials to drive the demand for cost-effective CRO services 116
TABLE 21 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE III STUDY 116
TABLE 22 PHASE III CLINICAL RESEARCH SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 117
TABLE 23 NORTH AMERICA: PHASE III CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 117
TABLE 24 EUROPE: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 117
TABLE 25 ASIA PACIFIC: PHASE III CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 118
TABLE 26 LATIN AMERICA: PHASE III CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 118
6.2.2 PHASE II CLINICAL RESEARCH SERVICES 118
6.2.2.1 Long duration of Phase II studies provides growth opportunities for CROs 118
TABLE 27 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE II STUDIES 119
TABLE 28 PHASE II CLINICAL RESEARCH SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 119
TABLE 29 NORTH AMERICA: PHASE II CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 120
TABLE 30 EUROPE: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 120
TABLE 31 ASIA PACIFIC: PHASE II CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 120
TABLE 32 LATIN AMERICA: PHASE II CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 121
6.2.3 PHASE I CLINICAL RESEARCH SERVICES 121
6.2.3.1 Robust pipeline of pharmaceutical companies driving the growth of this market segment 121
TABLE 33 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE I STUDIES 121
TABLE 34 PHASE I CLINICAL RESEARCH SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 122
TABLE 35 NORTH AMERICA: PHASE I CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 122
TABLE 36 EUROPE: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 123
TABLE 37 ASIA PACIFIC: PHASE I CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 123
TABLE 38 LATIN AMERICA: PHASE I CLINICAL RESEARCH SERVICES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 123
6.2.4 PHASE IV CLINICAL RESEARCH SERVICES 124
6.2.4.1 Increasing number of CROs are providing post-marketing surveillance 124
TABLE 39 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE IV CLINICAL STUDIES 124
TABLE 40 PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 125
TABLE 41 NORTH AMERICA: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 125
TABLE 42 EUROPE: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 125
TABLE 43 ASIA PACIFIC: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 126
TABLE 44 LATIN AMERICA: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 126
6.3 EARLY-PHASE DEVELOPMENT SERVICES 126
FIGURE 35 DRUGS IN PIPELINE, BY THERAPEUTIC AREA (2021) 127
TABLE 45 EXAMPLES OF EARLY-PHASE DEVELOPMENT SERVICES OFFERED BY MARKET PLAYERS 127
TABLE 46 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 128
TABLE 47 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 128
TABLE 48 NORTH AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 129
TABLE 49 EUROPE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 129
TABLE 50 ASIA PACIFIC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 129
TABLE 51 LATIN AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 130
6.3.1 CHEMISTRY, MANUFACTURING AND CONTROLS SERVICES 130
6.3.1.1 CMC services are widely used to check the quality standards of drugs 130
TABLE 52 CHEMISTRY, MANUFACTURING AND CONTROLS SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 130
TABLE 53 NORTH AMERICA: CHEMISTRY, MANUFACTURING AND CONTROLS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 131
TABLE 54 EUROPE: CHEMISTRY, MANUFACTURING AND CONTROLS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 131
TABLE 55 ASIA PACIFIC: CHEMISTRY, MANUFACTURING AND CONTROLS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 131
TABLE 56 LATIN AMERICA: CHEMISTRY, MANUFACTURING AND CONTROLS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 132
6.3.2 PRECLINICAL SERVICES 132
TABLE 57 PRECLINICAL SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 132
TABLE 58 PRECLINICAL SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 133
TABLE 59 NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 133
TABLE 60 EUROPE: PRECLINICAL SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 133
TABLE 61 ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 134
TABLE 62 LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 134
6.3.2.1 Pharmacokinetics/pharmacodynamics services 134
6.3.2.1.1 Importance of studies to determine the pharmacokinetic behavior of drug candidates is increasing 134
TABLE 63 PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 135
TABLE 64 NORTH AMERICA: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 135
TABLE 65 EUROPE: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 136
TABLE 66 ASIA PACIFIC: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 136
TABLE 67 LATIN AMERICA: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 136
6.3.2.2 Toxicology testing services 137
6.3.2.2.1 Demand for toxicology testing is increasing to prevent late-stage failures 137
TABLE 68 TOXICOLOGY TESTING SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 137
TABLE 69 NORTH AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 138
TABLE 70 EUROPE: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 138
TABLE 71 ASIA PACIFIC: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 138
TABLE 72 LATIN AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 139
6.3.2.3 Other preclinical services 139
TABLE 73 OTHER PRECLINICAL SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 139
TABLE 74 NORTH AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 140
TABLE 75 EUROPE: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 140
TABLE 76 ASIA PACIFIC: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 140
TABLE 77 LATIN AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 141
6.3.3 DISCOVERY STUDIES 141
6.3.3.1 Rising importance of CRO services for target identification and validation to promote segment growth 141
TABLE 78 DISCOVERY STUDIES MARKET, BY REGION, 2020–2027 (USD MILLION) 141
TABLE 79 NORTH AMERICA: DISCOVERY STUDIES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 142
TABLE 80 EUROPE: DISCOVERY STUDIES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 142
TABLE 81 ASIA PACIFIC: DISCOVERY STUDIES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 142
TABLE 82 LATIN AMERICA: DISCOVERY STUDIES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 143
6.4 LABORATORY SERVICES 143
TABLE 83 EXAMPLES OF LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS 143
TABLE 84 LABORATORY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 144
TABLE 85 LABORATORY SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 144
TABLE 86 NORTH AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 144
TABLE 87 EUROPE: LABORATORY SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 145
TABLE 88 ASIA PACIFIC: LABORATORY SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 145
TABLE 89 LATIN AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 145
6.4.1 ANALYTICAL TESTING SERVICES 146
TABLE 90 ANALYTICAL TESTING SERVICES MARKET, BY TYPE,
2020–2027 (USD MILLION) 146
TABLE 91 ANALYTICAL TESTING SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 146
TABLE 92 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 147
TABLE 93 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 147
TABLE 94 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 147
TABLE 95 LATIN AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 148
6.4.1.1 Physical characterization services 148
6.4.1.1.1 Demand for physical characterization is increasing to reduce the risk of product failure 148
TABLE 96 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 148
TABLE 97 NORTH AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 149
TABLE 98 EUROPE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 149
TABLE 99 ASIA PACIFIC: PHYSICAL CHARACTERIZATION SERVICES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 149
TABLE 100 LATIN AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 150
6.4.1.2 Raw material testing services 150
6.4.1.2.1 Demand for raw material testing services is increasing to ensure the quality and purity of raw materials 150
TABLE 101 RAW MATERIAL TESTING SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 150
TABLE 102 NORTH AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 151
TABLE 103 EUROPE: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 151
TABLE 104 ASIA PACIFIC: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 151
TABLE 105 LATIN AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 152
6.4.1.3 Batch release testing services 152
6.4.1.3.1 Comprehensive portfolio of batch release testing services offered by CROs to propel segment growth 152
TABLE 106 BATCH RELEASE TESTING SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 152
TABLE 107 NORTH AMERICA: BATCH RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 153
TABLE 108 EUROPE: BATCH RELEASE TESTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 153
TABLE 109 ASIA PACIFIC: BATCH RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 153
TABLE 110 LATIN AMERICA: BATCH RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 154
6.4.1.4 Stability testing services 154
6.4.1.4.1 Stability testing is used to ensure the long-term quality, safety, and efficacy of pharmaceutical products 154
TABLE 111 STABILITY TESTING SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 155
TABLE 112 NORTH AMERICA: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 155
TABLE 113 EUROPE: STABILITY TESTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 155
TABLE 114 ASIA PACIFIC: STABILITY TESTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 156
TABLE 115 LATIN AMERICA: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 156
6.4.1.5 Other analytical testing services 156
TABLE 116 OTHER ANALYTICAL TESTING SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 157
TABLE 117 NORTH AMERICA: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 157
TABLE 118 EUROPE: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 157
TABLE 119 ASIA PACIFIC: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 158
TABLE 120 LATIN AMERICA: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 158
6.4.2 BIOANALYTICAL TESTING SERVICES 158
6.4.2.1 Demand for bioanalytical testing has increased due to the growing use of macromolecules and biosimilars 158
TABLE 121 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 159
TABLE 122 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 159
TABLE 123 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 159
TABLE 124 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 160
TABLE 125 LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 160
6.5 CONSULTING SERVICES 160
6.5.1 ADOPTION OF CONSULTING SERVICES IS INCREASING FOR QUALITY ASSURANCE PURPOSES 160
TABLE 126 CONSULTING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 161
TABLE 127 NORTH AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 161
TABLE 128 EUROPE: CONSULTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 162
TABLE 129 ASIA PACIFIC: CONSULTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 162
TABLE 130 LATIN AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 162
6.6 DATA MANAGEMENT SERVICES 163
6.6.1 DATA MANAGEMENT SERVICES EXPECTED TO RECORD THE HIGHEST CAGR DURING THE FORECAST PERIOD 163
TABLE 131 EXAMPLES OF DATA MANAGEMENT SERVICES OFFERED BY PROMINENT PLAYERS 163
TABLE 132 DATA MANAGEMENT SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 164
TABLE 133 NORTH AMERICA: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 164
TABLE 134 EUROPE: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 164
TABLE 135 ASIA PACIFIC: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 165
TABLE 136 LATIN AMERICA: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 165
7 CRO SERVICES MARKET, BY THERAPEUTIC AREA 166
7.1 INTRODUCTION 167
TABLE 137 CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION) 167
7.2 ONCOLOGY 168
FIGURE 36 GLOBAL CANCER INCIDENCE, BY CANCER TYPE (2020) 168
FIGURE 37 NUMBER OF ONCOLOGY CLINICAL TRIALS STARTED GLOBALLY FROM
2011 TO 2021 (IN THOUSAND) 169
TABLE 138 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2021) 169
TABLE 139 CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2020–2027 (USD MILLION) 170
TABLE 140 CRO SERVICES MARKET FOR ONCOLOGY, BY REGION,
2020–2027 (USD MILLION) 170
TABLE 141 NORTH AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 170
TABLE 142 EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY,
2020–2027 (USD MILLION) 171
TABLE 143 ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 171
TABLE 144 LATIN AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 171
7.2.1 BREAST CANCER 172
7.2.1.1 Breast cancer is the most prevalent cancer 172
TABLE 145 CRO SERVICES MARKET FOR BREAST CANCER, BY REGION,
2020–2027 (USD MILLION) 172
TABLE 146 NORTH AMERICA: CRO SERVICES MARKET FOR BREAST CANCER,
BY COUNTRY, 2020–2027 (USD MILLION) 172
TABLE 147 EUROPE: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 173
TABLE 148 ASIA PACIFIC: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 173
TABLE 149 LATIN AMERICA: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 173
7.2.2 LUNG CANCER 174
7.2.2.1 Drug approvals indicate increasing research against lung cancer 174
TABLE 150 CRO SERVICES MARKET FOR LUNG CANCER, BY REGION,
2020–2027 (USD MILLION) 174
TABLE 151 NORTH AMERICA: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 174
TABLE 152 EUROPE: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY,
2020–2027 (USD MILLION) 175
TABLE 153 ASIA PACIFIC: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 175
TABLE 154 LATIN AMERICA: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 175
7.2.3 COLORECTAL CANCER 176
7.2.3.1 Increasing number of clinical trials on treatments against colorectal cancer to drive segment growth 176
TABLE 155 CRO SERVICES MARKET FOR COLORECTAL CANCER, BY REGION,
2020–2027 (USD MILLION) 176
TABLE 156 NORTH AMERICA: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 176
TABLE 157 EUROPE: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 177
TABLE 158 ASIA PACIFIC: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 177
TABLE 159 LATIN AMERICA: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 177
7.2.4 PROSTATE CANCER 178
7.2.4.1 Increasing research initiatives on prostate cancer to drive segment growth 178
TABLE 160 CRO SERVICES MARKET FOR PROSTATE CANCER, BY REGION,
2020–2027 (USD MILLION) 178
TABLE 161 NORTH AMERICA: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 178
TABLE 162 EUROPE: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 179
TABLE 163 ASIA PACIFIC: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 179
TABLE 164 LATIN AMERICA: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 179
7.2.5 OTHER CANCERS 180
TABLE 165 CRO SERVICES MARKET FOR OTHER CANCERS, BY REGION,
2020–2027 (USD MILLION) 180
TABLE 166 NORTH AMERICA: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2020–2027 (USD MILLION) 180
TABLE 167 EUROPE: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2020–2027 (USD MILLION) 181
TABLE 168 ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2020–2027 (USD MILLION) 181
TABLE 169 LATIN AMERICA: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2020–2027 (USD MILLION) 181
7.3 INFECTIOUS DISEASES 182
7.3.1 EPIDEMIC OUTBREAKS ARE NECESSITATING INCREASING DRUG DISCOVERY ACTIVITIES 182
TABLE 170 CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION,
2020–2027 (USD MILLION) 182
TABLE 171 NORTH AMERICA: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 182
TABLE 172 EUROPE: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 183
TABLE 173 ASIA PACIFIC: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 183
TABLE 174 LATIN AMERICA: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 183
7.4 CARDIOVASCULAR SYSTEM DISORDERS 184
7.4.1 HIGH MORTALITY RATES DRIVING PHARMACEUTICAL COMPANIES TO DEVELOP NEW TREATMENT OPTIONS 184
TABLE 175 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2021) 184
TABLE 176 CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2020–2027 (USD MILLION) 185
TABLE 177 NORTH AMERICA: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 185
TABLE 178 EUROPE: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 185
TABLE 179 ASIA PACIFIC: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 186
TABLE 180 LATIN AMERICA: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 186
7.5 NEUROLOGY 186
7.5.1 INCREASING INVESTMENT IN R&D AND GRANTS FOR NEUROLOGICAL DISORDERS TO DRIVE SEGMENT GROWTH 186
TABLE 181 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2021) 187
TABLE 182 CRO SERVICES MARKET FOR NEUROLOGY, BY REGION,
2020–2027 (USD MILLION) 188
TABLE 183 NORTH AMERICA: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 188
TABLE 184 EUROPE: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY,
2020–2027 (USD MILLION) 188
TABLE 185 ASIA PACIFIC: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 189
TABLE 186 LATIN AMERICA: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 189
7.6 VACCINES 189
7.6.1 INCREASING INVESTMENTS IN VACCINE R&D TO DRIVE SEGMENT GROWTH 189
TABLE 187 CRO SERVICES MARKET FOR VACCINES, BY REGION,
2020–2027 (USD MILLION) 190
TABLE 188 NORTH AMERICA: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2020–2027 (USD MILLION) 190
TABLE 189 EUROPE: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY,
2020–2027 (USD MILLION) 190
TABLE 190 ASIA PACIFIC: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY,
2020–2027 (USD MILLION) 191
TABLE 191 LATIN AMERICA: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2020–2027 (USD MILLION) 191
7.7 METABOLIC DISORDERS/ENDOCRINOLOGY 191
7.7.1 INCREASING GLOBAL DIABETES POPULATION EXPECTED TO DRIVE SEGMENT GROWTH 191
FIGURE 38 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES,
2000–2045 (MILLION) 192
TABLE 192 CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2020–2027 (USD MILLION) 192
TABLE 193 NORTH AMERICA: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 193
TABLE 194 EUROPE: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 193
TABLE 195 ASIA PACIFIC: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 193
TABLE 196 LATIN AMERICA: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 194
7.8 IMMUNOLOGICAL DISORDERS 194
7.8.1 GROWING DRUGS PIPELINE FOR IMMUNOLOGICAL DISORDERS TO DRIVE SEGMENT GROWTH 194
TABLE 197 CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2020–2027 (USD MILLION) 194
TABLE 198 NORTH AMERICA: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 195
TABLE 199 EUROPE: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 195
TABLE 200 ASIA PACIFIC: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 195
TABLE 201 LATIN AMERICA: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 196
7.9 PSYCHIATRY 196
7.9.1 RISING INCIDENCE OF PSYCHIATRIC DISORDERS TO PROPEL SEGMENT GROWTH 196
TABLE 202 CRO SERVICES MARKET FOR PSYCHIATRY, BY REGION,
2020–2027 (USD MILLION) 196
TABLE 203 NORTH AMERICA: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2020–2027 (USD MILLION) 197
TABLE 204 EUROPE: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY,
2020–2027 (USD MILLION) 197
TABLE 205 ASIA PACIFIC: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2020–2027 (USD MILLION) 197
TABLE 206 LATIN AMERICA: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2020–2027 (USD MILLION) 198
7.10 RESPIRATORY DISORDERS 198
7.10.1 INCREASING PREVALENCE OF RESPIRATORY DISORDERS TO SUPPORT SEGMENT GROWTH 198
TABLE 207 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISEASES (2021) 198
TABLE 208 CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION,
2020–2027 (USD MILLION) 199
TABLE 209 NORTH AMERICA: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 199
TABLE 210 EUROPE: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 200
TABLE 211 ASIA PACIFIC: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 200
TABLE 212 LATIN AMERICA: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 200
7.11 DERMATOLOGY 201
7.11.1 INCREASING PREVALENCE OF SKIN DISORDERS TO PROPEL SEGMENT GROWTH 201
TABLE 213 LIST OF PIPELINE DRUGS FOR SKIN DISEASES (2021) 201
TABLE 214 CRO SERVICES MARKET FOR DERMATOLOGY, BY REGION,
2020–2027 (USD MILLION) 202
TABLE 215 NORTH AMERICA: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 202
TABLE 216 EUROPE: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY,
2020–2027 (USD MILLION) 202
TABLE 217 ASIA PACIFIC: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 203
TABLE 218 LATIN AMERICA: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 203
7.12 OPHTHALMOLOGY 203
7.12.1 GROWING NEED FOR OPHTHALMOLOGY-RELATED CLINICAL TRIALS TO DRIVE SEGMENT GROWTH 203
TABLE 219 CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY REGION,
2020–2027 (USD MILLION) 204
TABLE 220 NORTH AMERICA: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 204
TABLE 221 EUROPE: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 204
TABLE 222 ASIA PACIFIC: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 205
TABLE 223 LATIN AMERICA: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 205
7.13 GASTROINTESTINAL DISEASES 205
7.13.1 RISING INCIDENCE OF GASTROINTESTINAL DISEASES TO PROPEL SEGMENT GROWTH 205
TABLE 224 CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2020–2027 (USD MILLION) 206
TABLE 225 NORTH AMERICA: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 206
TABLE 226 EUROPE: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 206
TABLE 227 ASIA PACIFIC: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 207
TABLE 228 LATIN AMERICA: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 207 1 INTRODUCTION 55 1.1 OBJECTIVES OF THE STUDY 55 1.2 MARKET DEFINITION 56 1.2.1 INCLUSIONS & EXCLUSIONS 56 1.3 MARKET SCOPE 57 FIGURE 1 CRO SERVICES MARKET 57 1.3.1 YEARS CONSIDERED FOR THE STUDY 58 1.4 CURRENCY 58 1.5 LIMITATIONS 58 1.6 STAKEHOLDERS 59 1.7 SUMMARY OF CHANGES 59 2 RESEARCH METHODOLOGY 61 2.1 RESEARCH DATA 61 FIGURE 2 RESEARCH DESIGN 61 2.1.1 SECONDARY DATA 62 2.1.2 PRIMARY DATA 62 FIGURE 3 CRO SERVICES MARKET: BREAKDOWN OF PRIMARIES 63 2.2 MARKET SIZE ESTIMATION 64 FIGURE 4 MARKET SIZE ESTIMATION—BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF CRO SERVICES IN THE MARKET 64 FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2021 64 FIGURE 6 AVERAGE MARKET SIZE ESTIMATION, 2021 65 2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST 66 FIGURE 7 CRO SERVICES MARKET: CAGR PROJECTIONS, 2022–2027 67 FIGURE 8 CRO SERVICES MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, AND OPPORTUNITIES 67 FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 68 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 69 FIGURE 10 DATA TRIANGULATION METHODOLOGY 69 2.5 INSIGHTS FROM PRIMARIES 70 FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS 70 2.6 RESEARCH ASSUMPTIONS 70 2.6.1 COVID-19-SPECIFIC ASSUMPTIONS 71 2.7 RISK ANALYSIS 71 3 EXECUTIVE SUMMARY 72 FIGURE 12 CRO SERVICES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 72 FIGURE 13 CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2022 VS. 2027 (USD MILLION) 73 FIGURE 14 CRO SERVICES MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 74 FIGURE 15 GEOGRAPHICAL SNAPSHOT: CRO SERVICES MARKET 75 4 PREMIUM INSIGHTS 76 4.1 CRO SERVICES MARKET OVERVIEW 76 FIGURE 16 RISING INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET GROWTH 76 4.2 NORTH AMERICA: CRO SERVICES MARKET SHARE, BY SERVICE & COUNTRY (2021) 77 FIGURE 17 CLINICAL RESEARCH SERVICES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN CRO SERVICES MARKET IN 2021 77 4.3 CRO SERVICES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 78 FIGURE 18 CLINICAL RESEARCH SERVICES SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2027 78 4.4 CRO SERVICES MARKET SHARE, BY END USER, 2021 78 FIGURE 19 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2021 78 4.5 CRO SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 79 FIGURE 20 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH IN THE CRO SERVICES MARKET FROM 2022 TO 2027 79 5 MARKET OVERVIEW 80 5.1 INTRODUCTION 80 5.2 MARKET DYNAMICS 80 FIGURE 21 CRO SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 80 TABLE 1 CRO SERVICES MARKET: IMPACT ANALYSIS 81 5.2.1 DRIVERS 81 5.2.1.1 Increasing investment in pharmaceutical R&D 81 FIGURE 22 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–2026 82 FIGURE 23 ACTIVE PHARMACEUTICAL PIPELINE, 2011–2021 83 5.2.1.2 Increasing number of clinical trial 83 FIGURE 24 NUMBER OF CLINICAL TRIALS REGISTERED WORLDWIDE (2000–2021) 83 5.2.1.3 High cost of in-house drug development 84 FIGURE 25 AVERAGE COST TO DEVELOP A PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 2010–2020 (USD BILLION) 84 5.2.1.4 Rising prevalence of orphan and rare diseases 85 5.2.2 OPPORTUNITIES 85 5.2.2.1 Growth in the drugs and biologics market despite the COVID-19 pandemic 85 FIGURE 26 TOTAL NUMBER OF NEW DRUGS (NEW CHEMICAL ENTITIES AND BIOLOGICS) APPROVED BY THE US FDA (2011–2021) 85 TABLE 2 LIST OF BIOLOGICS APPROVED BY THE US FDA (2021) 86 5.2.2.2 Rising demand for specialized testing services among end users 86 5.2.2.3 Need for novel clinical trial designs for complex cell and gene therapies 87 5.2.3 CHALLENGES 87 5.2.3.1 Shortage of skilled professionals for clinical trials 87 5.2.3.2 Requirement for unique analytical testing approaches for innovative formulations 88 5.2.4 MARKET TRENDS 88 5.2.4.1 Growing adoption of artificial intelligence-based tools for drug discovery 88 5.2.4.2 Increased outsourcing to emerging Asian economies 89 5.2.4.3 CRO industry consolidation 90 TABLE 3 LIST OF ACQUISITIONS 90 5.2.4.4 Integrated end-to-end R&D service solutions 91 5.3 RANGES/SCENARIOS 91 FIGURE 27 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE CRO SERVICES MARKET 91 5.4 IMPACT OF COVID-19 OUTBREAK ON THE CRO SERVICES MARKET 92 FIGURE 28 CRO SERVICES MARKET SCENARIO WITH AND WITHOUT COVID-19 IMPACT, 2019–2021 92 5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 94 FIGURE 29 REVENUE SHIFT & NEW POCKETS FOR CRO SERVICE PROVIDERS 94 5.6 PRICING ANALYSIS 94 TABLE 4 AVERAGE SELLING PRICE OF CRO SERVICES, BY REGION (2020) 95 5.7 VALUE CHAIN ANALYSIS 95 FIGURE 30 VALUE CHAIN ANALYSIS OF THE CRO SERVICES MARKET: CLINICAL RESEARCH PHASES ADD MAXIMUM VALUE 96 5.8 ECOSYSTEM ANALYSIS 97 FIGURE 31 ECOSYSTEM ANALYSIS: CRO SERVICES MARKET 97 TABLE 5 SUPPLY CHAIN ECOSYSTEM 98 5.9 TECHNOLOGY ANALYSIS 99 5.10 CASE STUDIES 100 5.10.1 COVANCE FSPX DATA ANALYSIS WAS USED TO DETERMINE THE ELIGIBILITY OF PATIENTS ENROLLED FOR ONCOLOGY CLINICAL TRIALS 100 5.10.2 IQVIA PROVIDES END-TO-END CLINICAL SUPPORT TO SPONSOR 100 5.11 KEY CONFERENCES & EVENTS IN 2022–2023 100 TABLE 6 CRO SERVICES MARKET: DETAILED LIST OF CONFERENCES & EVENTS 100 5.12 REGULATORY ANALYSIS 101 5.12.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 101 TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 101 TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 102 TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103 TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103 5.13 PORTER’S FIVE FORCES ANALYSIS 107 TABLE 11 CRO SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 107 5.13.1 THREAT OF NEW ENTRANTS 107 5.13.2 THREAT OF SUBSTITUTES 107 5.13.3 BARGAINING POWER OF BUYERS 108 5.13.4 BARGAINING POWER OF SUPPLIERS 108 5.13.5 DEGREE OF COMPETITION 108 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 109 5.14.1 KEY STAKEHOLDERS IN THE BUYING PROCESS 109 FIGURE 32 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS OF CRO SERVICES 109 5.14.2 BUYING CRITERIA FOR CRO SERVICES 109 FIGURE 33 KEY BUYING CRITERIA FOR END USERS 109 6 CRO SERVICES MARKET, BY TYPE 110 6.1 INTRODUCTION 111 TABLE 12 CRO SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 111 6.2 CLINICAL RESEARCH SERVICES 111 TABLE 13 NUMBER OF REGISTERED AND RECRUITING CLINICAL STUDIES AS OF MARCH 2022, BY LOCATION 112 TABLE 14 EXAMPLES OF CLINICAL RESEARCH SERVICES OFFERED BY MARKET PLAYERS 112 FIGURE 34 DRUGS IN PIPELINE, BY DEVELOPMENT PHASE, 2020 VS. 2021 113 TABLE 15 CLINICAL RESEARCH SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 114 TABLE 16 CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 114 TABLE 17 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 114 TABLE 18 EUROPE: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 115 TABLE 19 ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 115 TABLE 20 LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 115 6.2.1 PHASE III CLINICAL RESEARCH SERVICES 116 6.2.1.1 Rising cost of Phase III trials and high number of patients recruited in these trials to drive the demand for cost-effective CRO services 116 TABLE 21 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE III STUDY 116 TABLE 22 PHASE III CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 117 TABLE 23 NORTH AMERICA: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 117 TABLE 24 EUROPE: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 117 TABLE 25 ASIA PACIFIC: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 118 TABLE 26 LATIN AMERICA: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 118 6.2.2 PHASE II CLINICAL RESEARCH SERVICES 118 6.2.2.1 Long duration of Phase II studies provides growth opportunities for CROs 118 TABLE 27 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE II STUDIES 119 TABLE 28 PHASE II CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 119 TABLE 29 NORTH AMERICA: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 120 TABLE 30 EUROPE: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 120 TABLE 31 ASIA PACIFIC: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 120 TABLE 32 LATIN AMERICA: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 121 6.2.3 PHASE I CLINICAL RESEARCH SERVICES 121 6.2.3.1 Robust pipeline of pharmaceutical companies driving the growth of this market segment 121 TABLE 33 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE I STUDIES 121 TABLE 34 PHASE I CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 122 TABLE 35 NORTH AMERICA: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 122 TABLE 36 EUROPE: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 123 TABLE 37 ASIA PACIFIC: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 123 TABLE 38 LATIN AMERICA: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 123 6.2.4 PHASE IV CLINICAL RESEARCH SERVICES 124 6.2.4.1 Increasing number of CROs are providing post-marketing surveillance 124 TABLE 39 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE IV CLINICAL STUDIES 124 TABLE 40 PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 125 TABLE 41 NORTH AMERICA: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 125 TABLE 42 EUROPE: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 125 TABLE 43 ASIA PACIFIC: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 126 TABLE 44 LATIN AMERICA: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 126 6.3 EARLY-PHASE DEVELOPMENT SERVICES 126 FIGURE 35 DRUGS IN PIPELINE, BY THERAPEUTIC AREA (2021) 127 TABLE 45 EXAMPLES OF EARLY-PHASE DEVELOPMENT SERVICES OFFERED BY MARKET PLAYERS 127 TABLE 46 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 128 TABLE 47 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 128 TABLE 48 NORTH AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 129 TABLE 49 EUROPE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 129 TABLE 50 ASIA PACIFIC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 129 TABLE 51 LATIN AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 130 6.3.1 CHEMISTRY, MANUFACTURING AND CONTROLS SERVICES 130 6.3.1.1 CMC services are widely used to check the quality standards of drugs 130 TABLE 52 CHEMISTRY, MANUFACTURING AND CONTROLS SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 130 TABLE 53 NORTH AMERICA: CHEMISTRY, MANUFACTURING AND CONTROLS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 131 TABLE 54 EUROPE: CHEMISTRY, MANUFACTURING AND CONTROLS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 131 TABLE 55 ASIA PACIFIC: CHEMISTRY, MANUFACTURING AND CONTROLS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 131 TABLE 56 LATIN AMERICA: CHEMISTRY, MANUFACTURING AND CONTROLS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 132 6.3.2 PRECLINICAL SERVICES 132 TABLE 57 PRECLINICAL SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 132 TABLE 58 PRECLINICAL SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 133 TABLE 59 NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 133 TABLE 60 EUROPE: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 133 TABLE 61 ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 134 TABLE 62 LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 134 6.3.2.1 Pharmacokinetics/pharmacodynamics services 134 6.3.2.1.1 Importance of studies to determine the pharmacokinetic behavior of drug candidates is increasing 134 TABLE 63 PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 135 TABLE 64 NORTH AMERICA: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 135 TABLE 65 EUROPE: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 136 TABLE 66 ASIA PACIFIC: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 136 TABLE 67 LATIN AMERICA: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 136 6.3.2.2 Toxicology testing services 137 6.3.2.2.1 Demand for toxicology testing is increasing to prevent late-stage failures 137 TABLE 68 TOXICOLOGY TESTING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 137 TABLE 69 NORTH AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 138 TABLE 70 EUROPE: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 138 TABLE 71 ASIA PACIFIC: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 138 TABLE 72 LATIN AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 139 6.3.2.3 Other preclinical services 139 TABLE 73 OTHER PRECLINICAL SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 139 TABLE 74 NORTH AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 140 TABLE 75 EUROPE: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 140 TABLE 76 ASIA PACIFIC: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 140 TABLE 77 LATIN AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 141 6.3.3 DISCOVERY STUDIES 141 6.3.3.1 Rising importance of CRO services for target identification and validation to promote segment growth 141 TABLE 78 DISCOVERY STUDIES MARKET, BY REGION, 2020–2027 (USD MILLION) 141 TABLE 79 NORTH AMERICA: DISCOVERY STUDIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 142 TABLE 80 EUROPE: DISCOVERY STUDIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 142 TABLE 81 ASIA PACIFIC: DISCOVERY STUDIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 142 TABLE 82 LATIN AMERICA: DISCOVERY STUDIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 143 6.4 LABORATORY SERVICES 143 TABLE 83 EXAMPLES OF LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS 143 TABLE 84 LABORATORY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 144 TABLE 85 LABORATORY SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 144 TABLE 86 NORTH AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 144 TABLE 87 EUROPE: LABORATORY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 145 TABLE 88 ASIA PACIFIC: LABORATORY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 145 TABLE 89 LATIN AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 145 6.4.1 ANALYTICAL TESTING SERVICES 146 TABLE 90 ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 146 TABLE 91 ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 146 TABLE 92 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 147 TABLE 93 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 147 TABLE 94 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 147 TABLE 95 LATIN AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 148 6.4.1.1 Physical characterization services 148 6.4.1.1.1 Demand for physical characterization is increasing to reduce the risk of product failure 148 TABLE 96 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 148 TABLE 97 NORTH AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 149 TABLE 98 EUROPE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 149 TABLE 99 ASIA PACIFIC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 149 TABLE 100 LATIN AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 150 6.4.1.2 Raw material testing services 150 6.4.1.2.1 Demand for raw material testing services is increasing to ensure the quality and purity of raw materials 150 TABLE 101 RAW MATERIAL TESTING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 150 TABLE 102 NORTH AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 151 TABLE 103 EUROPE: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 151 TABLE 104 ASIA PACIFIC: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 151 TABLE 105 LATIN AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 152 6.4.1.3 Batch release testing services 152 6.4.1.3.1 Comprehensive portfolio of batch release testing services offered by CROs to propel segment growth 152 TABLE 106 BATCH RELEASE TESTING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 152 TABLE 107 NORTH AMERICA: BATCH RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 153 TABLE 108 EUROPE: BATCH RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 153 TABLE 109 ASIA PACIFIC: BATCH RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 153 TABLE 110 LATIN AMERICA: BATCH RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 154 6.4.1.4 Stability testing services 154 6.4.1.4.1 Stability testing is used to ensure the long-term quality, safety, and efficacy of pharmaceutical products 154 TABLE 111 STABILITY TESTING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 155 TABLE 112 NORTH AMERICA: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 155 TABLE 113 EUROPE: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 155 TABLE 114 ASIA PACIFIC: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 156 TABLE 115 LATIN AMERICA: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 156 6.4.1.5 Other analytical testing services 156 TABLE 116 OTHER ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 157 TABLE 117 NORTH AMERICA: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 157 TABLE 118 EUROPE: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 157 TABLE 119 ASIA PACIFIC: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 158 TABLE 120 LATIN AMERICA: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 158 6.4.2 BIOANALYTICAL TESTING SERVICES 158 6.4.2.1 Demand for bioanalytical testing has increased due to the growing use of macromolecules and biosimilars 158 TABLE 121 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 159 TABLE 122 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 159 TABLE 123 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 159 TABLE 124 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 160 TABLE 125 LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 160 6.5 CONSULTING SERVICES 160 6.5.1 ADOPTION OF CONSULTING SERVICES IS INCREASING FOR QUALITY ASSURANCE PURPOSES 160 TABLE 126 CONSULTING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 161 TABLE 127 NORTH AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 161 TABLE 128 EUROPE: CONSULTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 162 TABLE 129 ASIA PACIFIC: CONSULTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 162 TABLE 130 LATIN AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 162 6.6 DATA MANAGEMENT SERVICES 163 6.6.1 DATA MANAGEMENT SERVICES EXPECTED TO RECORD THE HIGHEST CAGR DURING THE FORECAST PERIOD 163 TABLE 131 EXAMPLES OF DATA MANAGEMENT SERVICES OFFERED BY PROMINENT PLAYERS 163 TABLE 132 DATA MANAGEMENT SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 164 TABLE 133 NORTH AMERICA: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 164 TABLE 134 EUROPE: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 164 TABLE 135 ASIA PACIFIC: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 165 TABLE 136 LATIN AMERICA: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 165 7 CRO SERVICES MARKET, BY THERAPEUTIC AREA 166 7.1 INTRODUCTION 167 TABLE 137 CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2020–2027 (USD MILLION) 167 7.2 ONCOLOGY 168 FIGURE 36 GLOBAL CANCER INCIDENCE, BY CANCER TYPE (2020) 168 FIGURE 37 NUMBER OF ONCOLOGY CLINICAL TRIALS STARTED GLOBALLY FROM 2011 TO 2021 (IN THOUSAND) 169 TABLE 138 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2021) 169 TABLE 139 CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2020–2027 (USD MILLION) 170 TABLE 140 CRO SERVICES MARKET FOR ONCOLOGY, BY REGION, 2020–2027 (USD MILLION) 170 TABLE 141 NORTH AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 170 TABLE 142 EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 171 TABLE 143 ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 171 TABLE 144 LATIN AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 171 7.2.1 BREAST CANCER 172 7.2.1.1 Breast cancer is the most prevalent cancer 172 TABLE 145 CRO SERVICES MARKET FOR BREAST CANCER, BY REGION, 2020–2027 (USD MILLION) 172 TABLE 146 NORTH AMERICA: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 172 TABLE 147 EUROPE: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 173 TABLE 148 ASIA PACIFIC: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 173 TABLE 149 LATIN AMERICA: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 173 7.2.2 LUNG CANCER 174 7.2.2.1 Drug approvals indicate increasing research against lung cancer 174 TABLE 150 CRO SERVICES MARKET FOR LUNG CANCER, BY REGION, 2020–2027 (USD MILLION) 174 TABLE 151 NORTH AMERICA: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 174 TABLE 152 EUROPE: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 175 TABLE 153 ASIA PACIFIC: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 175 TABLE 154 LATIN AMERICA: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 175 7.2.3 COLORECTAL CANCER 176 7.2.3.1 Increasing number of clinical trials on treatments against colorectal cancer to drive segment growth 176 TABLE 155 CRO SERVICES MARKET FOR COLORECTAL CANCER, BY REGION, 2020–2027 (USD MILLION) 176 TABLE 156 NORTH AMERICA: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 176 TABLE 157 EUROPE: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 177 TABLE 158 ASIA PACIFIC: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 177 TABLE 159 LATIN AMERICA: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 177 7.2.4 PROSTATE CANCER 178 7.2.4.1 Increasing research initiatives on prostate cancer to drive segment growth 178 TABLE 160 CRO SERVICES MARKET FOR PROSTATE CANCER, BY REGION, 2020–2027 (USD MILLION) 178 TABLE 161 NORTH AMERICA: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 178 TABLE 162 EUROPE: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 179 TABLE 163 ASIA PACIFIC: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 179 TABLE 164 LATIN AMERICA: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 179 7.2.5 OTHER CANCERS 180 TABLE 165 CRO SERVICES MARKET FOR OTHER CANCERS, BY REGION, 2020–2027 (USD MILLION) 180 TABLE 166 NORTH AMERICA: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2020–2027 (USD MILLION) 180 TABLE 167 EUROPE: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2020–2027 (USD MILLION) 181 TABLE 168 ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2020–2027 (USD MILLION) 181 TABLE 169 LATIN AMERICA: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2020–2027 (USD MILLION) 181 7.3 INFECTIOUS DISEASES 182 7.3.1 EPIDEMIC OUTBREAKS ARE NECESSITATING INCREASING DRUG DISCOVERY ACTIVITIES 182 TABLE 170 CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION) 182 TABLE 171 NORTH AMERICA: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 182 TABLE 172 EUROPE: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 183 TABLE 173 ASIA PACIFIC: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 183 TABLE 174 LATIN AMERICA: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 183 7.4 CARDIOVASCULAR SYSTEM DISORDERS 184 7.4.1 HIGH MORTALITY RATES DRIVING PHARMACEUTICAL COMPANIES TO DEVELOP NEW TREATMENT OPTIONS 184 TABLE 175 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2021) 184 TABLE 176 CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2020–2027 (USD MILLION) 185 TABLE 177 NORTH AMERICA: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 185 TABLE 178 EUROPE: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 185 TABLE 179 ASIA PACIFIC: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 186 TABLE 180 LATIN AMERICA: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 186 7.5 NEUROLOGY 186 7.5.1 INCREASING INVESTMENT IN R&D AND GRANTS FOR NEUROLOGICAL DISORDERS TO DRIVE SEGMENT GROWTH 186 TABLE 181 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2021) 187 TABLE 182 CRO SERVICES MARKET FOR NEUROLOGY, BY REGION, 2020–2027 (USD MILLION) 188 TABLE 183 NORTH AMERICA: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 188 TABLE 184 EUROPE: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 188 TABLE 185 ASIA PACIFIC: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 189 TABLE 186 LATIN AMERICA: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 189 7.6 VACCINES 189 7.6.1 INCREASING INVESTMENTS IN VACCINE R&D TO DRIVE SEGMENT GROWTH 189 TABLE 187 CRO SERVICES MARKET FOR VACCINES, BY REGION, 2020–2027 (USD MILLION) 190 TABLE 188 NORTH AMERICA: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2020–2027 (USD MILLION) 190 TABLE 189 EUROPE: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2020–2027 (USD MILLION) 190 TABLE 190 ASIA PACIFIC: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2020–2027 (USD MILLION) 191 TABLE 191 LATIN AMERICA: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2020–2027 (USD MILLION) 191 7.7 METABOLIC DISORDERS/ENDOCRINOLOGY 191 7.7.1 INCREASING GLOBAL DIABETES POPULATION EXPECTED TO DRIVE SEGMENT GROWTH 191 FIGURE 38 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES, 2000–2045 (MILLION) 192 TABLE 192 CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2020–2027 (USD MILLION) 192 TABLE 193 NORTH AMERICA: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 193 TABLE 194 EUROPE: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 193 TABLE 195 ASIA PACIFIC: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 193 TABLE 196 LATIN AMERICA: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 194 7.8 IMMUNOLOGICAL DISORDERS 194 7.8.1 GROWING DRUGS PIPELINE FOR IMMUNOLOGICAL DISORDERS TO DRIVE SEGMENT GROWTH 194 TABLE 197 CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2020–2027 (USD MILLION) 194 TABLE 198 NORTH AMERICA: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 195 TABLE 199 EUROPE: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 195 TABLE 200 ASIA PACIFIC: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 195 TABLE 201 LATIN AMERICA: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 196 7.9 PSYCHIATRY 196 7.9.1 RISING INCIDENCE OF PSYCHIATRIC DISORDERS TO PROPEL SEGMENT GROWTH 196 TABLE 202 CRO SERVICES MARKET FOR PSYCHIATRY, BY REGION, 2020–2027 (USD MILLION) 196 TABLE 203 NORTH AMERICA: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2020–2027 (USD MILLION) 197 TABLE 204 EUROPE: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2020–2027 (USD MILLION) 197 TABLE 205 ASIA PACIFIC: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2020–2027 (USD MILLION) 197 TABLE 206 LATIN AMERICA: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2020–2027 (USD MILLION) 198 7.10 RESPIRATORY DISORDERS 198 7.10.1 INCREASING PREVALENCE OF RESPIRATORY DISORDERS TO SUPPORT SEGMENT GROWTH 198 TABLE 207 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISEASES (2021) 198 TABLE 208 CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2020–2027 (USD MILLION) 199 TABLE 209 NORTH AMERICA: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 199 TABLE 210 EUROPE: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 200 TABLE 211 ASIA PACIFIC: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 200 TABLE 212 LATIN AMERICA: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 200 7.11 DERMATOLOGY 201 7.11.1 INCREASING PREVALENCE OF SKIN DISORDERS TO PROPEL SEGMENT GROWTH 201 TABLE 213 LIST OF PIPELINE DRUGS FOR SKIN DISEASES (2021) 201 TABLE 214 CRO SERVICES MARKET FOR DERMATOLOGY, BY REGION, 2020–2027 (USD MILLION) 202 TABLE 215 NORTH AMERICA: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 202 TABLE 216 EUROPE: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 202 TABLE 217 ASIA PACIFIC: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 203 TABLE 218 LATIN AMERICA: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 203 7.12 OPHTHALMOLOGY 203 7.12.1 GROWING NEED FOR OPHTHALMOLOGY-RELATED CLINICAL TRIALS TO DRIVE SEGMENT GROWTH 203 TABLE 219 CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY REGION, 2020–2027 (USD MILLION) 204 TABLE 220 NORTH AMERICA: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 204 TABLE 221 EUROPE: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 204 TABLE 222 ASIA PACIFIC: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 205 TABLE 223 LATIN AMERICA: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 205 7.13 GASTROINTESTINAL DISEASES 205 7.13.1 RISING INCIDENCE OF GASTROINTESTINAL DISEASES TO PROPEL SEGMENT GROWTH 205 TABLE 224 CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2020–2027 (USD MILLION) 206 TABLE 225 NORTH AMERICA: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 206 TABLE 226 EUROPE: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 206 TABLE 227 ASIA PACIFIC: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 207 TABLE 228 LATIN AMERICA: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 207